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Resumen
Según la Organización Mundial de la Salud (OMS), cada año nacen de forma pre-
matura alrededor de 15 millones de bebés, cifra que va en aumento, entre otros
factores, por el incremento de técnicas de reproducción asistida o la cada vez
mayor edad materna. Las complicaciones derivadas del nacimiento prematuro son
la principal causa de mortalidad en niños menores de cinco años, responsables
de aproximadamente 1 millón de muertes en 2015. En un nacimiento prematuro
los bebés presentan complicaciones por la inmadurez de sus órganos, entre ellos
los pulmones, los cuales presentan un déficit de surfactante pulmonar, siendo ésta
la causa de la enfermedad conocida como Síndrome de Distrés Respiratorio
(SDR). Esta sustancia que recubre la superficie alveolar se genera de forma gra-
dual a partir de las 22 semanas de gestación y su función es la de reducir la tensión
superficial y, por consiguiente, la presión necesaria para la expansión del alveolo,
facilitando la respiración.
El tratamiento empleado en la actualidad para el tratamiento del Síndrome
de Distrés Respiratorio (SDR) en bebés prematuros conlleva riesgos que pueden
causarles daños permanentes. Este tratamiento consiste en intubar al neonato
para someterlo a ventilación mecánica y en administrarle surfactante pulmonar
mediante instilación intratraqueal. Aunque este tratamiento reduce el índice de
morbilidad y mortalidad, la instilación intratraqueal de surfactante está asociada
con efectos adversos que pueden causar lesiones pulmonares y cerebrales. Con el
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objetivo de evitar o minimizar los riesgos de éste tratamiento se están investigando
técnicas alternativas más seguras. Entre éstas técnicas, una posible alternativa con
gran potencial es la administración del surfactante en forma de aerosol,
simultaneándolo con un método de ventilación no-invasivo. Ello permitiría una
mínima manipulación de las vías respiratorias del neonato y una administración
del surfactante de forma menos agresiva. Hasta la fecha se han llevado a cabo
diferentes estudios clínicos que han mostrado la seguridad y viabilidad de ésta
técnica. Sin embargo, los resultados obtenidos son dispares, lo cual puede deberse,
entre otros motivos, a las diferencias en el dispositivo empleado para generar el
aerosol, el uso de distintas preparaciones de surfactante (natural vs sintético) o
el emplazamiento del dispositivo nebulizador. El estudio de la administración de
surfactante en forma de aerosol conlleva la investigación y desarrollo de nuevos
dispositivos de nebulización. Concretamente los dispositivos de nebulización
tipo ‘jet’, también denominados neumáticos o de chorro de aire.
El trabajo de esta tesis se ha desarrollado tanto en el campo experimental
como en el campo numérico. Primero, se ha realizado un estudio experimental
in vitro de una técnica de nebulización para generar aerosoles de forma menos
invasiva en neonatos a través de un catéter de inhalación. También, se ha definido
un modelo numérico, basado en técnicas CFD (Computational Fluid Dynamics) a
través del código comercial STAR-CCM+, para su futura aplicación en la mejora
del diseño del dispositivo nebulizador propuesto. Tras el diseño y fabricación del
prototipo nebulizador mediante técnicas de fabricación aditiva, se ha llevado a
cabo un estudio experimental para analizar las características en tamaño y masa
de las gotas transportadas en el aerosol. Por último, se han establecido pautas para
la optimización de nuevos diseños de nebulizadores y se ha realizado la fabricación
de varios prototipos.
Inicialmente se llevó a cabo un estudio experimental con un dispositivo
de nebulización ya existente, el catéter de inhalación IC-1.1 (Aeroprobe, Trudell
Medical International). Destacar que el uso de este catéter estaba limitado para su
xx
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uso en investigación o experimentación en animales y que fue retirado del mercado.
Este catéter tiene una longitud de 1 metro y está formado por un lumen central,
por donde se suministra el compuesto a nebulizar, y por seis lúmenes exteriores
por donde se introduce aire comprimido (Ver Figura 1). El estudio se ha realizado
empleando tres diferentes compuestos; agua destilada (H2Od), perfluorodecalina
(PFD) y FC75. Estos dos últimos compuestos son perflurocarbonos (PFC), los
cuales han demostrado su eficacia en diversos estudios para el tratamiento del
SDR.
Figure 1: (a) Sección distal de la punta del IC-1.1 y (b) simplificación definida
para la generación del dominio computacional axisimétrico.
Para la caracterización del tamaño y masa de las gotas generadas por el IC-
1.1 se ha empleado un espectrómetro, concretamente el modelo APS 3321 con
capacidad para medir partículas comprendidas entre 0-20 µm. Los parámetros
que se han medido son el diámetro aerodinámico (Da), el diámetro de la masa
media aerodinámica (MMAD) y la desviación estándar geométrica (GSD). El Da
se define como el diámetro que tendría que tener la gota si fuera esférica y tuviera
una densidad de 1 g/cm3 para ir a la misma velocidad que la gota original. Por
otro lado, el MMAD se define como el valor del diámetro aerodinámico que divide
la masa del aerosol en partes iguales, es decir, el 50% de la masa del aerosol es
transportada por gotas mayores o menores a ese valor. La GSD indica la dispersión
del tamaño de las gotas. Si su valor es 1 significa que el aerosol está formado por
gotas del mismo tamaño (aerosol monodisperso) mientras que un valor mayor que
1 indica que el aerosol está formado por gotas de diferentes tamaños (aerosol
heterodisperso).
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Los ensayos experimentales se han llevado a cabo con valores de presión entre 4
y 6 bares. Para cada compuesto y valor de presión se tomaron cinco muestras con
un tiempo de muestreo para cada prueba de 10 segundos. Los resultados del Da
para el agua destilada mostraron un suave incremento proporcional a la presión
mientras que los valores del MMAD variaban entre 10-11 µm. Por otra parte, para
ambos PFCs, el valor del Da descendió con un aumento de la presión de 4 a 5 bares.
Respecto al MMAD, el PFD mostró valores estables con un incremento de presión.
Sin embargo, el FC75 ofreció un descenso significativo en el valor del MMAD al
aumentar la presión. En todos los casos se generaba un aerosol heterodisperso
atendiendo a los resultados de la GSD. La Figura 2 recoge los resultados del valor
medio del Da y del MMAD obtenidos para cada compuesto.
(a) (b)
Figure 2: (a) Resultados del D¯a y (b) MMAD obtenidos a la distancia óptima
para cada compuesto y presión. Los valores están dados como media ± desviación
estándar.
De forma complementaria al estudio experimental, se ha realizado un estu-
dio numérico con técnicas CFD para estudiar las características del aerosol
generado con el IC-1.1. Se ha definido un dominio computacional axisimétrico
compuesto por los últimos 2 mm del IC-1.1 y la región aguas abajo del catéter.
Para la definición de la fase discreta se han creado diez inyectores uniformemente
distribuidos a lo largo de una línea de longitud igual al radio del lúmen central del
IC-1.1 (34.3 µm). La velocidad de inyección de las gotas es igual a la velocidad de
la fase continua en esa posición.
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Tras el correspondiente estudio de dependencia de la malla, se ha generado un
mallado no estructurado del dominio con un refinamiento en la región cercana a
la punta del catéter y a lo largo de todo el eje central, donde se acumulará gran
parte del aerosol. Para la resolución del flujo continuo de aire se ha utilizado
el enfoque euleriano, mientras que para la resolución de las gotas del aerosol
dispersas en el aire se ha empleado el enfoque lagrangiano. Se utilizaron las
ecuaciones promediadas de Navier-Stokes para la resolución de los flujos turbu-
lentos y más concretamente el modelo k- realizable. Del mismo modo, también
se incluyó un modelo adicional para predecir la dispersión de la fase discreta por
la turbulencia. Las trayectorias de las gotas inyectadas se resolvieron teniendo en
cuenta la influencia de la fase discreta en el flujo continuo (two-way coupling) y el
modelado de la rotura secundaria del aerosol se realizó a través del modelo Taylor
Analogy Breakup. La Figura 3 ilustra la simulación del aerosol formado por el
IC-1.1 para el compuesto FC75 y una presión de 4 bares. Para la validación de
los resultados numéricos se han empleado los resultados experimentales realizados
previamente.
Figure 3: Visualización del aerosol de FC75 formado a una presión de 4 bares.
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Este modelo numérico, desarrollado para la simulación del flujo de aerosol
formado por el IC-1.1, servirá de base para futuros estudios computacionales con
nuevos dispositivos nebulizadores como los que se presentan a continuación.
Inicialmente se ha estudiado la viabilidad y limitaciones actuales que ofrecen las
técnicas de fabricación aditiva para el desarrollo de un prototipo nebulizador
con capacidad para generar un aerosol de las características requeridas. Tras la
realización de múltiples pruebas, se consideró la tecnología de impresión PolyJet
como la solución óptima para llevar a cabo la fabricación de los dos prototipos
propuestos. El diseño del Prototipo 1 consiste en un lúmen central, por el que
circula el compuesto a nebulizar, y seis lúmenes exteriores, por los que circula el
aire comprimido. Por otro lado, en el Prototipo 2, los lúmenes exteriores han sido
reemplazados por dos semi-anillos con un área equivalente. La Figura 4 muestra
el resultado de la fabricación de los prototipos, con el detalle de la sección distal
para cada uno de ellos.
Figure 4: (a)Visualización general del prototipo nebulizador fabricado, detalle de
la sección distal del (b) Prototipo 1 y (c) Prototipo 2.
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Una vez fabricados los prototipos de forma satisfactoria se ha procedido a
realizar una serie de ensayos experimentales con el objetivo de estudiar su
funcionamiento y las características del aerosol generado. El montaje experimental
empleado es similar al utilizado previamente en el estudio con el IC-1.1. Ambos
prototipos han sido estudiados con agua destilada (H2Od), PFD y FC75 y las
propiedades del aerosol han sido estudiadas a través del Da, el MMAD y el GSD.
Durante la nebulización de H2Od, el MMAD de los aerosoles producidos con
el Prototipo 1 proporcionó valores por debajo de 9 µm mientras que para el Pro-
totipo 2 los valores del MMAD aumentaban hasta las 15 µm. En lo que respecta
al Da, los resultados obtenidos con el Prototipo 1 mantienen un valor estable inde-
pendientemente de la presión aplicada mientras que para el Prototipo 2 se observó
un ligero incremento en el valor del Da proporcional a la presión.
La Figura 5 muestra los resultados del Da y el MMAD obtenidos para los
aresoles de PFD y FC75 producidos con cada uno de los prototipos. Con respecto al
MMAD, los dos prototipos mostraron valores relativamente uniformes con ambos
compuestos, cercanos a 12 µm, para los dos valores de presión estudiados (Ver
Figura 5a). Los resultados del Da de los aerosoles producidos con el Prototipo 2
fueron ligeramente menores que los obtenidos con el Prototipo 1, encontrándose
en todos los casos por debajo de las 5 µm (Ver Figura 5b).
(a) (b)
Figure 5: (a) Valores del MMAD (µm) y (b) Da (µm) para el Prototipo 1 y el
Prototipo 2 en función de la presión aplicada con el compuesto PFD y FC75. Los
valores están dados como media ± desviación estándar.
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Tras los resultados obtenidos con estos dos prototipos, se han establecido las
directrices y pautas para la optimización del diseño del prototipo ne-
bulizador. Para ello, y teniendo en cuenta las limitaciones de la tecnología de
fabricación aditiva empleada, se han propuesto una serie de modificaciones con el
objetivo de mejorar el funcionamiento del prototipo y las características del aerosol
generado.
A lo largo de este proceso se han fabricado cuatro nuevos prototipos que, al
igual que con el Prototipo 1 y el Prototipo 2, fueron realizados en colaboración
con la empresa OPTIMUS 3D. En el Prototipo 4.2, entre otros cambios, se ha
modificado la longitud total del prototipo, se ha añadido un pequeño redondeo
en la sección distal del semi-anillo por donde circula el aire comprimido y se ha
incluido un estrechamiento en los últimos 2 mm del lúmen central con el objetivo
de aumentar el tiempo del proceso de nebulización. Con este nuevo diseño se ha
llevado a cabo un ensayo experimental con un neumotacógrafo para estudiar los
valores de presión distal, ya que es de suma importancia que la presión intrapul-
monar no supere los 10 cmH2O. Trabajando con presiones máximas de 0.5 bares
se consiguió un valor de presión distal de 5 cmH2O y un tiempo de nebulización
aproximado de cinco minutos y medio para los 5 ml de compuesto suministrado.
La siguiente etapa de optimización del diseño se centró en la mejora de la
conectividad y manejo del prototipo nebulizador. Dada la fragilidad del material
empleado para la fabricación de los prototipos, su conexión para el ensayo experi-
mental era bastante delicada. Por ello, el Prototipo 6 se fabricó conjuntamente
con un postizo roscado para realizar la conexión por donde se suministra el com-
puesto a nebulizar. Adicionalmente, también se realizaron modificaciones en las
dimensiones distales del prototipo. Una vez conseguida su fabricación de forma
satisfactoria y realizadas pruebas experimentales se observó una obstrucción en el
lúmen central y problemas de fabricación derivados por la limitación tecnológica
para tal nivel de detalle.
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Por dichos motivos, se decidió simplificar el diseño del prototipo nebulizador
con el objetivo de reducir el número de variables que pueden afectar a la correcta
fabricación del dispositivo, y por lo tanto, a su funcionamiento. Se han desarrollado
dos últimos diseños (Prototipo 8 y Prototipo 9) en los cuáles se ha eliminado el
postizo conector y se ha aumentado el espesor de material entre el lúmen central
y el semi-anillo. Adicionalmente se han rediseñado las pestañas que se incluyeron
en ambas entradas del prototipo para mejorar su conexión dentro del montaje
experimental. Ambos prototipos se consiguieron fabricar de forma satisfactoria y
se comprobó que su funcionamiento era correcto y con potencial para generar un
proceso de nebulización.
La presión aplicada al prototipo juega un papel determinante en el funcionamiento
de los prototipos diseñados en la presente tesis. Por este motivo se ha implemen-
tado para futuros estudios un sistema de control de presión a través de dos
válvulas proporcionales. Este sistema permite controlar en tiempo real tanto la
presión aplicada al pistón situado dentro de la cámara de líquido como la presión
de aire suministrado a través del semi-anillo.
Los resultados obtenidos mediante las técnicas desarrolladas en la presente tesis
doctoral han sido publicados en varias revistas indexadas en la Journal Citation
Report (JCR) de alto factor impacto. Asimismo, también se han presentado parte
de los resultados en dos congresos internacionales (ver Apéndice B).
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CHAPTER 1
INTRODUCTION
1.1 Neonatal Respiratory Distress Syndrome
According to the World Health Organization (WHO), every year an estimated 15
million babies are born preterm, i.e. before 37 completed weeks of gestation, and
this number is rising over the years due to several factors. Recently, Arroyo et al.
[1, 2] studied the impact of air pollution on low birth weight in Spain and concluded
that 1.35% of premature births that ocurred in Spain can be attributed to air
pollution. There are sub-categories of preterm birth, based on gestational age:
moderate to late preterm babies born between 32 and 37 completed weeks, very
preterm babies born between 28 and 32 completed weeks and extremely preterm
babies born earlier than the 28th week of the gestational age. Respiratory distress
syndrome (RDS) of the newborn is the leading cause of death in premature infants
[3]. Extremely and very preterm infants present cerebral and pulmonary issues
due to the immaturity of the lungs, primarily due to lack of surfactant, a natural
substance indispensable to breath. The respiratory tract esentially consists of a
series of bifurcating pipes, with the pipes becoming smaller and smaller towards
the alveolar region, where it takes place the gas exchange.
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The risk and severity of respiratory distress syndrome is inversely proportional
to the gestational age of infant birth. Young gestational age and very low birth
weight (from 1001 to 1500g), or extremely low birth weight (from 500 to 1000g),
respectively, are the biggest risk factors for RDS. There are also others risk fac-
tors for developing RDS, such as maternal diabetes, multiple births, male sex or
second twin. For instance, RDS does not affect sex and races equally. Males are
more predisposed than females, although the exact physiological cause is not yet
understood. In the study of Miller et al. [4], the RDS incidence was more than
three times higher in boys than in girls. Black fetuses, historically, have had a
lower incidence of RDS and develop surfactant faster than white fetuses [5].
Any preterm newborn displaying some of these symptoms should be considered
highly suspect for having RDS:
• Abnormal breathing patterns (such as tachypnea or apnea).
• Grunting (occurring during each exhalation by breathing against a partially
closed glottis).
• See-saw breathing pattern (the stomach and chest are moving out of synch
during breathing attempts).
• Substernal and/or intercostal retractions.
• Nasal flaring.
• Hypoxemia (low level of oxygen in the blood).
• Hypercarbia (high level of carbon dioxide in the blood).
• Cyanosis (appearance of blue or purple coloration of the skin).
• Atelectasis (collapse or closure of a lung resulting in reduced or absent gas
exchange).
If the RDS remains on time, other adversities can be reported as bronchopul-
monary dysplasia (BPD) [6], pulmonary hemorrhage, pneumothorax [7] or pul-
monary vasoconstriction.
2
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1.2 Pulmonary Surfactant
Three basic regions can be defined in the respiratory tract. Figure 1.1 shows the
structure and elements of the respiratory system.
1. The extrathoracic region (also referred as ’upper airways’), which includes
the oral cavity, the nasal cavity and the larynx (containing the vocal cords).
2. The tracheo-bronchial region (also referred as ’lower airways’), containing
the trachea and the bronchi until the so-called ’terminal bronchioles’.
3. The alveolar region.
Figure 1.1: Human respiratory tract from the upper airways to the alveolar
region. Source: Kleinstreuer et al. [8].
The alveoli are coated with pulmonary surfactant which is secreted by the
type II alveolar cells. It reduces the surface tension and, therefore, it prevents
the alveolar collapse at the end of the exhalation, retaining enough air (functional
residual capacity) to start the next breath. Without the surfactant the surface
tension at the alveoli would remain high and they would collapse.
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Surfactant is a complex substance which appears in fetal development during
the saccular phase (gestation weeks 24 to 34) and whose major components are
lipids (90%) and proteins (10%) [9]. Most of the lipids are phospholipids being
the dipalmitoylphosphatidylcholine (DPPC) the predominant one and the main
component responsible for decreasing the surface tension. The proteins consist
of four unique surfactant-associated proteins: SP-A, SP-B, SP-C and SP-D. Two
of them (SP-A and SP-D) are hydrophilic proteins involved in pulmonary host
defense [10] and the other two (SP-B and SP-C) play an intricate role in sustaining
alveolar ventilation [11]. Parra and Pérez-Gil [12] made a detailed review of the
composition, structure and properties of the surfactant and problems due to its
inactivation. The pulmonary surfactant have three main functions:
1. Increase the pulmonary compliance.
2. Prevent the collapse of the lung at the end of expiration (atelectasis) by
reducing the surface tension at the air-liquid interface of the alveolus.
3. Facilitate the recruitment of collapsed airways.
The lung compliance, which describes how volume changes for a given change
in pressure, is an important parameter to check if the newborn has respiratory
problems, taking into account that surfactant deficiency reduces this parameter
as shown in Figure 1.2 [13]. The behavior of the alveoli is largely dictated by
Laplace’s Law, which relates the alveolar pressure, the surface tension and the
alveoli radius by the Equation 1.1.
Palv =
2σ
ralv
(1.1)
The surfactant capacity to reduce the surface tension allows to maintain the
same alveolar internal pressure and, therefore, prevents the collapse. In cases
of surfactant deficiency the surface tension remains high for all the alveoli and,
according to the Laplace Law expressed by the Equation 1.1, the pressure in the
smaller ones is higher. That means that the air is going from the smaller alveoli to
a bigger one, causing the collapse of the first one at the end of the expiration. This
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Figure 1.2: Reduced compliance of preterm infant suffering from RDS in
comparison to a healthy term newborn baby. Source: Kramer et al. [13].
directly affects to the gas exchange produced in the alveolar region, the carbon
dioxide increase (hypercarbia) and the oxygen supply decrease (hypoxia).
1.3 Current Medical Treatment
The nowadays known as RDS was first characterized in the early 20th century
as hyaline membrane disease because most physicians in that time thought that
newborn’s death cause was the hyaline membranes which were found in their lungs
at autopsy. However, in 1959 Avery and Mead [14] discovered that the surfactant
deficiency was the responsible of this disease. This finding gave a chance to further
studies and to develop the surfactant replacement therapy.
The treatment can start even before the delivery, with the use of antenatal
corticosteroids in women at risk of preterm birth. Corticosteroids accelerate the
surfactant development and the fetal lung maturation. Reviews of the literature
show that a repeated dose of prenatal corticosteroids given to women who remain
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Figure 1.3: Surfactant influence in the alveoli stability.
at risk of an early birth helps the baby’s lungs and reduces serious health problems
in the first few weeks of life [15]. Nevertheless, there is currently no clear or agreed-
upon best type of corticosteroid or dose. After delivery, the treatment includes
the instillation of surfactant as well as ventilatory support techniques depending
on the gestational age of the newborn and its clinical state.
1.3.1 Surfactant Replacement Therapy
In 1929, Von Neergaard [16] showed that more pressure was required to inflate
lungs with air than with an aqueous solution like water. Throughout the Young-
Laplace Law (Equation 1.1), he found that surface tension at the boundary of the
moist tissue of the lung and the air was the reason for the difference in pressure
needed for the lungs to expand. In 1955, Pattle [17] speculated that ’absence of the
lining substance may sometimes be one of the difficulties with which a premature
baby has to contend’. In 1959, Avery and Mead discovered that RDS was caused
by the absence of surfactant [14]. Just four years later, in 1963, the United States
President John F. Kennedy’s son death, due to RDS, two days after he was born,
put a new focus on diseases of the newborn. Since then, different studies were
carried out in order to find a treatment. In 1969 Robillard et al. [18] and later
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Shannon and Bunnell [19] treated a small number of infants, but their results did
not encourage them to continue these studies. Enhorning and Robertson in 1972
[20] showed a significant improvement in pulmonary mechanics using surfactant
in prematurely born rabbit pups. It was not until 1980 when Fujiwara et al.
[21] made the first successful clinical study with the surfactant replacement
therapy. Some years later, in 1990, after an intense study and development, the
guidelines on the management of surfactant replacement therapy were published
and are constantly being updated after critical examination of the most up-to-date
evidence available [22]. The aim of this management is to provide interventions
that will maximize survival whilst minimizing potential adverse effects resulting
in a considerably decrease on chronic lung diseases. The therapy consists in the
introduction of exogenous surfactant (surfactant originated outside the lungs) in
the preterm infant lung. Usually bovine or porcine natural surfactant administered
by intratracheal instillation (also called bolus) through an endotracheal tube as the
one illustrated in Figure 1.4a.
(a) (b)
Figure 1.4: (a) Endotracheal tube with a catheter to instill the surfactant and (b)
endotracheal tube position within the trachea [23].
McDonald and Ainsworth [24] summarized information about the type of sur-
factant and dose recommended as well as the surfactant benefits in other neonatal
lung diseases. Recently, Polin et al. [25] made a clinical report reviewing a num-
ber of important topics surrounding the use of surfactant, including prophylactic
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versus rescue replacement and preparations and administration techniques.
There are several types of surfactant preparations licensed for use in babies
with RDS (See Table 1.1). Nowadays the guideline recommends the use of natural
surfactant, instead of synthetic, as early as possible in the course of RDS. Ma et
al. [26] summarized the results of a number of trials comparing natural versus
synthetic surfactants and trials comparing different natural surfactants. It was
also reported a survival advantage with higher initial doses of natural surfactant
(200mg/kg better than 100mg/kg using poractant alfa) and a fewer requirement
of a second dose [27]. Recently, Tridente et al. [28] performed a review to compare
the efficiency between porcine and bovine surfactant to treat RDS in preterm
infants. Their results showed that 200 mg/kg of poractant alfa is associated with
better respiratory outcomes compared to bovine surfactants. Although there are
a number of barriers involved in the development of a protein-containing synthetic
surfactant, the quest to find a suitable preparation continues. It would present
some advantages as the capacity to produce surfactant in large quantities, a cost
reduction compared with natural surfactant and the opportunity to control its
composition in order to reduce the risk of transmission of infections.
The timing of surfactant replacement therapy has been a controversial topic and
research. There are two main strategies for initiation of surfactant replacement.
• Prophylactic strategy
Therapy begins as soon as possible in newborns at high risk for developing
RDS. This method has been shown to decrease the need for mechanical
ventilation (MV) and lower the incidence of BPD and death.
• Rescue strategy
Therapy begins when it exists a clear evidence of RDS. Evidences include
oxygen requirements, and/or a chest radiography with characteristic RDS
features. The benefit of this option includes the potential to avoid intubation
in some patients and less time on MV.
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Generic name Trade name Source Dose (Volume)
Pumactant ALEC Synthetic No longer manufactured
Bovactant Alveofact Bovine 50 mg/kg/dose (1.2 ml/kg)
Bovine lipid ex-
tract surfactant
BLES Bovine 135 mg/kg/dose (5 ml/kg)
Poractant alfa Curosurf Porcine 100-200 mg/kg/dose (1.25-
2.5 ml/kg)
Colfosceril
palmitate
Exosurf Synthetic 64 mg/kg/dose (5 ml/kg)
Calfactant Exosurf Synthetic 64 mg/kg/dose (5 ml/kg)
Surfactant-TA Surfacten Bovine 105 mg/kg/dose (3 ml/kg)
Lucinactant Surfaxin Synthetic Not licensed
Beractant Survanta Bovine 100 mg/kg/dose (4 ml/kg)
Table 1.1: Surfactant preparations and recommended doses.
The surfactant replacement therapy has been proven effective but it also presents
some important drawbacks. The main issue is that it requires the intubation of
the newborn and the application of ventilatory support techniques, as mechanical
ventilation, which may induce lung injuries and/or chronic diseases even in short
periods of application. Other drawbacks are the impossibility to interact with the
patient, a newborn, to execute the intubation maneuver and the administration of
the dose in bolus form, that may affect cerebral and systemic hemodynamic pa-
rameters [29]. The bolus can also clogged the endotracheal tube and/or the upper
airways, contributing to an oxygen deficiency and an increase in carbon dioxide
values. Obladen and Halliday [30, 31] summarized the history of surfactant up
to 1980 and from 1980 respectively, with the most important landmarks in the
research of the RDS disease and its treatment.
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1.3.2 Ventilatory Support
The aim of ventilatory support in neonates is the same as for any other patient. Fa-
cilitate alveolar ventilation, improve gas exchange, and reduce the work to breathe.
Briefly, ventilatory supports are classified in two types.
• Invasive ventilation: where the intubation of the patient is made.
• Non-invasive ventilation: where other devices, as cannulas or masks, are
used instead of intubation.
The invasive ventilation, also known as mechanical ventilation (MV), is an
important resource to treat neonates with acute RDS, even though the use of an-
tenatal corticosteroids and the improvement in non invasive ventilatory support
techniques has decreased the use of this type of ventilation. A mechanical venti-
lator is an automated device that provides all, or part, of the work of breathing
for patients with impaired respiratory or neurologic function. The MV allows to
control the peak inspiratory pressure (PIP) in each inspiration or the tidal volume
(Vt), known as the normal volume of air displaced between normal inhalation and
exhalation when extra effort is not applied. This last one is the less harmful and
most used parameter when MV is applied.
However, the use of MV has some side effects, especially in preterm infants
because of their small lung size [32]. Some of them are the appearance of BPD,
infections or even in some cases brain damage [33]. The optimal strategy for MV
use in RDS is not clear, since it expands the lung and care should be taken to use
minimal pressures and volumes not to force it. The use of MV can also affect the
generation speed of surfactant and their properties [34]. For that reason, MV has
to be removed as soon as possible when the neonate shows signs of recovery. Due
to all of these adverse effects derived from MV, the non-invasive ventilation (NIV)
techniques have become an extremely popular alternative for the RDS treatment.
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The most known methods are the following:
• Continuous Positive Airway Pressure (CPAP).
• Nasal Intermittent Positive Pressure Ventilation (NIPPV).
• High Flow Nasal Cannula (HFNC).
The CPAP technique, firstly described by Gregory et al. [35], consists in
the application of positive pressure (between 5-10 cmH2O) to the airways of the
spontaneously breathing patient throughout the respiratory cycle. It is applied via
an endotracheal tube positioned in a non invasive way, by means of nasal cannulas
or mask, among other devices. In this way, the work of breathing of the neonates
decreases, assuring a certain pressure in the alveoli and achieving lung stability.
It is crucial to control the pressure combined by the CPAP and the spontaneously
breathing in order to be small enough to avoid lung injuries [36].
The NIPPV method, which adds a second level of pressure delivery at regular
intervals to the patient, was found to be more effective than CPAP in weaning
infants with RDS from MV [37]. Further studies and randomized control trials are
required to use this method as an alternative to treat RDS [38]. About the HFNC,
there are a number of concerns that make no advisable their use in neonates. The
impossibility to control the pressure delivered to the infant, which may result in
lung overexpansion, and the lack of randomized control trials to assess its safety
and effectivity are the main ones [39].
Therefore, the most NIV method employed currently is the CPAP, even though
it also has some limitations. CPAP should not be considered, for example, in
infants who have already met the criteria for ventilatory failure or those who
have an unstable respiratory drive with frequent episodes of apnea that cause
desaturation and bradycardia. But the most important limitation is that CPAP
and surfactant replacement therapy are not compatible. At this point, a
question comes to mind to the neonatologists. Will initial stabilization of breathing
with CPAP be better than early intubation and surfactant treatment for very
preterm infants? [40].
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Nowadays, the technological progress makes possible to synchronize these me-
thods of NIV to the neonate spontaneously breathing. Neurally Adjusted Ven-
tilatory Assist (NAVA) is a unique approach to MV based on neural respiratory
output. The electrical activity of the diaphragm is captured, fed to the ventilator
and used to assist the patient’s breathing in synchrony and in proportion to the
patient’s own efforts. A desirable feature for the neonate to face the moment of
weaning from the MV [41].
1.4 State of the Art
The surfactant replacement therapy, with the use of MV or CPAP, has been proven
as a good treatment to reduce the incidence of RDS and mortality in preterm
infants. However, the intubation and use in some cases of MV has contributed to
an increase of deep lung and cerebral injuries. To avoid these side effects, new less
invasive surfactant administration alternatives and directions are being studied
[42].
1.4.1 Alternative Techniques of Surfactant Administration
1.4.1.1 INSURE Technique
One alternative therapy is the INSURE technique (INtubate, SURFactant, Extu-
bate) firstly reported by Verder et al. [43] in 1994. It consists in intubating the
preterm infant for surfactant administration with quick (within 10 minutes) extu-
bation to CPAP. Dani et al. [44] made a clinical study with 125 infants classifying
them into three groups; infants treated with MV, infants treated with INSURE
technique and infants treated only with CPAP. They showed that most of the
infants of their study could be treated with INSURE technique with a minimal
failure percentage. Sandri et al. [45] published a randomized controlled trial to
evaluate the efficacy of combining prophylactic surfactant and early selective sur-
factant, with CPAP in preterm infants. Their results showed that prophylactic
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surfactant given within 30 minutes of birth was not superior to early selective
surfactant in terms of requirement of MV in the first 5 days of life.
1.4.1.2 Use of Perfluorocarbons
Another alternative is the use of perfluorocarbons (PFC) instead of surfactant.
Burkhardt et al. [46] have demonstrated that are useful to improve surfactant
distribution and that resulted in a improved oxygenation.
1.4.1.3 Minimally Invasive Surfactant Therapies (MIST)
The upsurge use of non invasive ventilation techniques in preterm babies, as CPAP,
has led to the study of new minimally invasive surfactant therapies (MIST). These
potential strategies of surfactant administration include:
• Intra-amniotic instillation.
• Pharyngeal instillation.
• Surfactant administration via a laryngeal mask airway surfactant.
• Surfactant administration via a thin endotracheal catheter without intermit-
tent positive pressure ventilation.
• Nebulised surfactant administration in spontaneously breathing infants.
The tracheal catheterization is the most extensively method studied so far.
Dargaville et al. [47] developed the Hobart method, where Curosurf surfactant at
a dose of 100 mg/kg is administered using a semi-rigid vascular catheter briefly
passed into the trachea beyond the vocal cords. The results showed that surfac-
tant can be effectively delivered by this technique with a considerably reduction of
intubation and MV in the first 72 hours [48]. Kribs et al. [49] are also pioneers in
the use of MIST via tracheal catheterization. This approach was implemented in
several centers across Germany producing good outcomes, including a reduction
in MV [50]. In 2011, the results of an open-label randomised controlled trial with
preterm infants between 26 and 28 weeks, showed the feasibility and subsequent
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reduction in MV, during day 2 or 3 after birth, with the application of surfac-
tant to spontaneously breathing preterm infants by this procedure [51]. Recently,
this group has carried out an additional randomized controlled trial comparing
the results of two groups. The control group received conventional endotracheal
intubation during MV and the intervention group received surfactant via a thin
catheter according to their method. Although an increased rate of survival with-
out BPD (which was the primary outcome of the study) was not demonstrated
in the intervention group, an increased rate of survival without major compli-
cations was observed as well as a reduction in need and duration of MV [52].
Kanmaz et al. [53] have also been investigating the surfactant administration via
thin catheter through a randomized controlled trial, the Take Care trial. They
compared a group receiving the MIST with another one receiving the INSURE
technique. Their results showed also a reduction in MV requirement in first 72
hours of life and lower BPD rate in comparison with INSURE technique. Herting
et al. [54] summarized briefly the MIST technique, also known as LISA technique
(Less Invasive Surfactant Administration) with the clinical results of some of the
aforementioned clinical trials.
The development in the last years of new aerosol devices and surfactant formu-
lations has increased the attention on inhalation therapies to replace and improve
the current bolus instillation technique, as suggested in 2004 by Dhand [55]. The
administration of nebulised surfactant is a promising technique to treat lung
diseases and especially RDS even though there are still technical problems and
challenges to lead. Five clinical trials have been published so far in which
preterm infants have been treated with these techniques.
1. Surfactant Aerosol Treatment of RDS in Spontaneously Breathing
Premature infants.
This was the first study and it was carried out by Jorch et al. [56] in 1997.
20 preterm infants from 28 to 35 weeks were enrolled in the trial with a
median birth weight of 1,680 g. Surfactant nebulization was done using a
jet nebulizer via a nasopharyngeal tube. A commercially natural bovine
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surfactant was used and a time of nebulization of 20-50 minutes with two
doses of 150 mg/kg each one. The CPAP ventilation started between 1 and 7
hours of age and surfactant administration started between 2 and 9 hours of
age. Once the nebulization of surfactant started it was noted an immediate
improvement in oxygenation and alveolar ventilation. All infants survived
and endotracheal intubation and MV was avoided in 70% of them. One
limitation of this study is that only 10% of nebulized surfactant entered the
pharyngeal tube.
2. Inhalation of Aerosolized Surfactant to Neonates Treated with
CPAP.
In this study carried out by Arroe et al. [57] in 1998, 22 preterm infants
between 23 and 36 weeks were treated, delivering 108-864 mg of synthetic
surfactant (Exosurf) via aerosol by a jet nebulizer and using CPAP as ven-
tilatory support. No benefits were shown in the patients.
3. Pilot Study of Nebulized Surfactant Therapy for Neonatal RDS.
In the clinical study of Berggren et al. [58] performed in 2000, 32 preterm
infants between 27-34 weeks were randomized in two groups, 16 not receiving
surfactant and 16 receiving 480 mg of nebulized surfactant. All of them were
firstly supported with CPAP. Natural porcine surfactant (Curosurf) was used
and the aerosol was generated with a jet nebulizer and administered via the
CPAP equipment into the nostrils of the patient. No beneficial effects of
aerosolized surfactant were demonstrated. One limitation of this study was
the late administration of the surfactant, at a mean postnatal age of 19
hours.
4. An Open Label, Pilot Study of Aerosurf Combined with nCPAP
to Prevent RDS in Preterm Neonates.
Finer et al. [59] in 2010 evaluated the safety and feasibility of administering
Aerosurf (synthetic surfactant) by a vibrating membrane aerosol generator,
in combination with CPAP to 17 preterm infant of 28-32 weeks at risk for
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RDS. 11 preterm infants were enrolled to the Treatment Group 1, receiving
20 mg/ml of Aerosurf constantly over 3 hours with three additional treat-
ments allowed in the next 48 hours, with each treatment separated by at
least 3 hours. The other 6 preterm infants were enrolled to the Treatment
Group 2, receiving the same treatment but with the additional treatments
separated by a minimum of only 1 hour. The treatment of both groups
was initiated within 30 minutes of birth. It was shown that the administra-
tion of Aerosurf via nCPAP was safe and feasible but they were unable to
conclude whether the patients improvement was due to the nCPAP or the
administration of nebulized surfactant.
5. Nebulised Surfactant to Reduce Severity of Respiratory Distress:
A Blinded, Parallel, Randomised Controlled Trial.
Minocchieri et al. [60] in 2018 carried out a randomised control trial to
evaluate the efficacy of nebulized surfactant treatment. 606 preterm infants
with 29-33 weeks were assessed for eligibility but only 64 were enrolled in the
study. 32 preterm infants were allocated to receive CPAP (control group) and
other 32 to receive CPAP and nebulized surfactant via a customised vibrating
membrane nebulizer. The efficiency of nebulized surfactant in the first 4
hours was evaluated and the results showed that surfactant nebulization
reduced the requirement for intubation within 72 hours.
All these clinical trials have shown that surfactant administration by aerosoliza-
tion is a safe and feasible technique, although only the studies of Jorch et al. [59]
and Minocchieri et al. [60] have demonstrated the efficacy and benefits of surfac-
tant administration via aerosol. Currently, Dargaville et al. [61] are working in
another clinical study, the OPTIMIST-A trial, which is expected to be completed
in December 2021. In this study, the control group will be treated only with
CPAP whereas the intervention group will receive 200 mg/kg of poractant alfa
(Curosurf) administered under direct laryngoscopy using a surfactant instillation
catheter. Furthermore, Sood et al. [62] are performing a randomized clinical trial
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to analyze the efficacy of bovine surfactant aerosol administration and they have
already published the results of Phase I. The aerosol was administered through
short binasal prongs from a low flow jet nebulizer placed in the inspiratory limb.
17 preterm infants were enrolled, tolerated the aerosol treatment and 15 of them
completed the study with a significant improvement in physiological parameters.
One of the main reasons of the low efficiency of nebulized surfactants
in the clinical trials is the relative low lung deposition rates (less than 1% of the
mass nebulized) with conventional jet and ultrasonic nebulizers [63, 64]. Recently,
Tiemersma et al. [65] have checked that the lung deposition with a vibrating mesh
nebulizer prototype for babies is quite higher (between 18% and 20.5%). Several
factors influence in this lack of lung deposition in preterm infants:
1. Particles tend to deposit in the walls of the respiratory tract due to the small
dimensions of preterm infants airways.
2. Particles too small could be exhalated due to their high respiratory rate.
3. Their small lung volume.
4. No possible interaction and communication with the patient.
5. The requirement of specialized medical devices for their use in neonates.
6. The viscous characteristics of the surfactant which worsen the efficiency of
nebulizers.
7. Nebulizers could inactivate the properties of the surfactant.
To achieve satisfactory results with nebulized surfactant therapy it is important
to take into account some aspects as:
1. Size of the particles.
2. Type of surfactant.
3. Choice of surfactant nebulizer.
4. Length of treatment.
5. Dose of surfactant.
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The size of the particles have a major importance in terms of lung depo-
sition. Inhaled particles may deposit in various regions of the respiratory system
mainly by three deposition mechanisms: inertial impaction, gravitational settling
and diffusion, as shown in Figure 1.5. Each time the airflow changes due to a
bifurcation in the airways, the suspended particles tend to travel along their origi-
nal path due to inertia and may impact on an airway surface. Inertial impaction
occurs mostly with larger particles that are very close to airway walls, near the
first airway bifurcations. Therefore, deposition by impaction is usually produced
in the bronchial region. Deposition by sedimentation occurs in the smaller airways
of the bronchioles and alveoli, where the air flow is low and airway dimensions are
small. The sedimentation rate is dependent on the terminal settling velocity of
the particles, so sedimentation plays a greater role in deposition of particles with
larger aerodynamic diameters. Diffusion is the primary mechanism of deposition
for particles less than 0.5 µm in diameter. Diffusion is the net transport of par-
ticles from a region of high concentration to a region of lower concentration due
to Brownian motion, which is the random wiggling motion of a particle due to
the constant bombardment of air molecules. Diffusional deposition occurs mostly
when particles have just entered the nasopharynx, and it is also most likely to
occur in the smaller airways of the pulmonary region, where air flow is low.
Stahlhofen et al. [67] measured the total lung deposition as a function of
particle size. Radioactively labeled particles between 1-10 µm were administered
in three male adults measuring the particle sizes through a photometer technique.
The results showed that, for particles larger than 10 µm, deposition occurred due
to inertial impaction in the oropharyngeal region whereas particles of 5-10 µm
tended to be deposited in the tracheo-bronchial region. Only particles with less
than 5 µm reached the alveolar region. Salma et al. [68] also studied the effect
of particle mass size distribution on the deposition of aerosols in the respiratory
system for adults and a 5-year-old child. Particles in the aerodynamic size range
of 1-5 µm are considered respirable. However, small particles in combination with
short and low inspiratory flows increase the risk of exhalation drug losses.
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Figure 1.5: Deposition mechanisms of particles in the respiratory tract.
Source: Verma et al. [66].
The ventilation set-up and the position of the nebulizers in the ventila-
tor circuit also affect on aerosol drug delivery and their lung deposition. Winter-
halter et al. [69] established an in vitro model to evaluate the amount of aerosol
delivered through an endotracheal tube. They also studied whether or not differ-
ent ventilator modes and types of endotracheal tubes influence the aerosol delivery
performance. Two methods were applied to integrate the nebulizer into the venti-
lation circuit. In the first one (set-up A) the ultrasonic nebulizer is placed between
the endotracheal tube and the ventilator circuit whereas in the second one (set-up
B) it is placed at the same way but using a bypass. The results showed that
set-up B was not clearly superior to set-up A with respect to the total output at
the tip of the endotracheal tube. The reason of these results was that the ad-
vantage provided by the bypass circuit, releasing aerosol during inhalation, was
almost eliminated because a large amount of aerosol was accumulated inside the
additional tubing. Ari et al. [70] assessed different aerosol generator devices at 3
locations in humidified and non-humidified circuits during adult mechanical ven-
tilation: between the endotracheal tube and the Y-piece; 15 cm from Y-piece; and
15 cm from the ventilator. The results showed that during mechanical ventilation
the optimal drug delivery efficiency depends on the aerosol generator, the ven-
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tilator circuit, and the aerosol generator position. Murgia et al. [71], recently,
studied the influence of four different ventilation strategies on aerosol production
rate. Surfactant and three PFCs were aerosolized during mechanical ventilation
by means of three intratracheal inhalation catheters (IC) with different air flow
rates. The results showed that higher respiratory rates (RR) and higher peak in-
spiratory pressures (PIP) might enhance surfactant and PFC delivery to the lungs
but might also increase compound loss during the expiratory phase.
1.4.2 Aerosol Drug Delivery Devices
The main goal of these devices is to produce an aerosol with the sufficient size and
mass in their droplets and therefore, to be carried to the distal lung or deposited on
proximal airways to give rise to a therapeutic effect. This route of administration
provides low doses of an aerosolize drug with a quick clinical response without
many side effects. They are commonly divided into three types, as described by
Martin et al. [72]:
1. Pressurized metered dose inhaler (pMDI).
2. Dry powder inhaler (DPI).
3. Nebulizers.
• Jet nebulizers.
• Ultrasonic nebulizers.
• Vibrating mesh nebulizers.
The pMDI device consists of a canister, a metering chamber, and an ac-
tuator with a mouthpiece, as illustrated in Figure 1.6. Medication is found in
solution with a liquified gas propellant (hydrofluoroalkane [HFA]) and is housed
in a pressured canister fitted with a metering valve. The pressure needed for the
aerosolization of the medication is created in the canister by shaking the device to
disperse the liquefied gas propellant into the medication solution. As the canister
is depressed into the plastic actuator, one metered dose of medication is delivered
in a high-velocity spray via the actuator nozzle to the mouthpiece.
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The high-velocity aerosol plume only lasts 100 − 400 milliseconds as the size
of particles continues to diminish due to the evaporation of the HFA propellant.
Aerosolized particles may diminish in size from 45 µm at the actuator nozzle
to 0.5 µm 6 inches from the mouthpiece. Particle size is a key determinant of
the respirable dose. Larger particles (>10 µm) are highly likely to remain in the
oropharynx; midsized particles (5-10 µm) remain in the upper large bronchial tree,
while those of optimum size (1-5 µm) reach the lower airways. Smaller particles (≤
0.5 µm) are not deposited in the lungs but are instead exhaled as a gas. However,
even with a correct inhaler technique, most pMDIs only deposit 10-20% of the
labeled dose in the lungs; much of the medication remains in the mouth and
oropharynx, potentially leading to local and systemic adverse effects.
Figure 1.6: Scheme of a pressurized metered dose inhaler (pMDI).
Source: Dolovich et al. [73].
The purpose of the Dry Powder Inhalers (DPI) is to insert a prescribed
dose of powder aerosol into the air inhaled by a patient during a single breath [74].
Normally, the powder is delivered during a single, large breath. So it also requires
a good coordination by the patient to use it appropiately and, therefore, it is not
suitable to be used in neonatal population.
Nebulizers are devices that convert a liquid in solution or suspension into
small droplets. The main advantage in the face of pDMI and DPI is that they do
not need the interaction of the patient as well as the coordination of inhalation/ex-
halation to obtain an optimum delivery. As it has been seen above, they can be
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sorted in three different types according to the power source used to produce the
breakup of the liquid [75]. O’Callaghan and Barry [76] analyzed how they work
and described some of the most important parameters to define an aerosol and
some methods of measuring particle size, aerosol deposition and nebulizer output.
Jet nebulizers are based on the Bernoulli principle. A pressurized flow of gas,
generally air, is directed through a constricted orifice where the velocity of the air-
flow is increased to create a jet stream. This jet stream creates a sub-atmospheric
pressure zone (vacuum) which draws the fluid up the capillary tube. The impact
of a jet stream with the liquid and the extreme difference in velocity between them
produces aerosol particles or droplets.
Figure 1.7: Schematic of a conventional jet nebulizer. Source: Martin et al. [72].
Ultrasonic nebulizers remove the need for a compressed air source and, instead,
a high-frequency vibration generated by a piezoelectric crystal is used to the for-
mation of droplets. They present some troubles, as the significant heating of the
nebulizer solution and difficulties with nebulizing high-viscosity liquids. For these
reasons, this type of nebulizer was rapidly dismissed as an option for our case due
to the viscous characteristics and heat-sensitive of the surfactants.
Vibrating mesh nebulizers force liquid medications through multiple apertures
in a mesh or aperture plate in order to generate an aerosol. They present 2-3 times
higher lung depositions than classic jet nebulizers and are able to nebulize in low
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drug volumes. Despite all of these advantages they still present some challenges.
For instance, viscous drugs can clog the pores, cleaning the mesh can be difficult
and are more expensive than the other alternatives. Tiemersma et al. [65] evalua-
ted lung deposition of salbutamol using two vibrating mesh nebulizers, designed
specifically for use in preterm infants, and they compared them with a jet nebuli-
zer and a pMDI. The results showed that lung deposition was significantly higher
for the investigational vibrating mesh nebulizers in an in vitro model of a preterm
infant of 32-weeks gestational age.
Recently, Syedain et al. [77] developed a novel aerosol generator for surfac-
tant aerosol delivery in preterm infants. Even though this device still requires
the intubation of the neonate it showed promising results, with the generation of
small aerosol droplets and operating with low airflow. Milesi et al. [78] have also
worked in this direction developing a new atomizing device, consisting of a small
multilumen catheter, for intracorporeal nebulization of surfactant during CPAP.
In a recent research, they conducted a study to deliver nebulized surfactant with-
out the need of intubation in spontaneously breathing preterm lambs, showing
encouraging results [79].
1.5 Application of CFD Techniques in Human
Respiratory Airways
The definition of numerical models by means of Computational Fluid Dynamics
(CFD) tools provides a helpful methodology to analyze several health issues.
Specifically, in the study of respiratory diseases as the RDS, a numerical model
validated with experimental data is a highly valuable source of information about
the aerosol particles behavior within the respiratory tract.
Relatively little work has been performed in modeling pharmaceutical aerosols
in neonatal subjects. The smaller size of the preterm infants’ airways and the
difference of breathing conditions affect parameters such as the air flow velocity
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and particle transport and, therefore, do not make it possible to extrapolate the
results obtained from adult airways. Allen et al. [80] studied in 2004, with the help
of CFD tools, the airflow in an in vitro model of a five-year-old pediatric subject.
In the treatment of respiratory diseases, Longest et al. [81] in 2006 created a
CFD numerical model to evaluate the deposition patterns in the airways of a
four-year-old child under healthy and constricted conditions. De Jongh et al. [82]
obtained, by means of computed tomography, the geometry of the upper airways of
a nine-month-old infant to calculate the deposition of microparticles and compared
them with experimental results (See Figure 2.9a). Liu et al. [83] studied, with a
CFD model, the airflow patterns and the deposition of particles in the first three
generations of a pediatric upper respiratory tract. Their results showed higher
velocity fields, deposition rates and impaction numbers in comparison with those
observed in adults. This numerical model was validated with experimental data
taken from the study of Golshahi et al. [84].
In the last years, Tsega [85] has compared the respiratory airflow characteristics
in tracheobronchial airways of infant (6 months old), child (5-years-old) and adult
(25-years-old) reflecting that as age increases, airflow velocity, pressure and wall
shear stress decrease for both inspiration and expiration in this subregion of the
respiratory tract. Similarly, Deng et al. [86] have compared the particle deposition
in upper and lower airways in an infant (7-months-old), a child (4-years-old) and
an adult (20-years-old). They observed that the highest deposition values were ob-
tained in an infant, with most of the particles deposited in the upper airways due to
inertial impaction. Bass et al. [87] printed a 3D model with the nasal airways of a
6-months-old infant to carry out in vitro experiments, as illustrated in Figure 2.9b,
and used a CFD model to study the transport and deposition of micrometer-sized
aerosol particles. The CFD results were validated with the in vitro experiments
and concluded that aerosol particles with an aerodynamic diameter around 1.5 µm
are ideal to be delivered through an infant nasal cannula with high-efficiency lung
delivery. The aerosolization of surfactant was also analyzed with a CFD model
by Goikoetxea et al. [88] using a multi-lumen inhalation catheter with minimal
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manipulation of the airways. They corroborated the feasibility of this device to
generate a surfactant aerosol with an adequate size and validated the CFD model
with experimental data, providing optimization guidelines.
(a) Saint model. (b) Bass model.
Figure 1.8: Saint model of a 9 month-old infant upper airways [82] and (b) nasal
airways model from a 6 month-old infant [87].
The research in this field is more extensive in adult airways, using CFD tools
to study the influence of modified geometries, respiratory patterns, particle sizes
and different types of devices in lung deposition. Oldham et al. [89] studied the
influence of parameters such as the breathing rate and the particle size on particle
deposition in the respiratory tract. Koombua et al. [90] explored the influence
of airway wall elasticity analyzing two cases, rigid and flexible wall, respectively.
It was observed that the pressure within the airways was affected, but not the
air flow velocity or the wall shear stress. Recently, Elcner et al. [91] developed
a CFD model validated with experimental results of the inspiratory airflow in a
model from the throat to the fourth generation of the respiratory tract. Feng and
Kleinstreuer [92] studied the deposition, interaction, and transport of particles in
triple bifurcations, by means of the dense discrete phase model and the discrete
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element method. Walenga et al. [93] evaluated with a CFD study the deposition
fraction delivered with a pMDI and a DPI to healthy and constricted airways.
Both inhalers provided very low drug dose (1.13% and 1.08% respectively) and
was even lower in constricted airways. Delvadia et al. [94] varied the angle in
the positioning of a pMDI and DPI device. They highlighted the influence of this
inclination on the speed, size and, therefore, on the deposition of particles.
1.6 Thesis Motivation
The Department of Neonatal Physiology of the BioCruces Health Research Insti-
tute is working since 1988 in the study of the RDS and the postnatal lung maturity.
The research staff have more than 20 years of experience in the administration of
surfactant experimentally and clinically, evaluating new minimally invasive sur-
factant therapies in order to improve the RDS treatment in preterm infants. As a
result, they are authors of high quality contributions in the field. They were the
first to compare the administration of natural versus synthetic surfactant in imma-
ture lambs [95]. Additionally, they have observed for the first time that a standard
dose of surfactant for established RDS delivered as an aerosol can produce similar
response to rapid intratracheal bolus instillation of the same dose [96]. They also
have studied recently the impact of different surfactant administration techniques
on the cerebral oxygenation [97].
Since 2008, as a result of some research projects (SAIOTEK) funded by the
Basque Government (Spain), they explored the administration of aerosolized sur-
factant. Given the necessity for a specific nebulizer to nebulize surfactant in the
pediatric population, the research group came to the conclusion in 2011 to de-
velop a nebulizer prototype. The manufacturing of a device able to generate
an aerosol of surfactant in pediatric population would mark a milestone in the
treatment of preterm infants affected with RDS. In fact, taking into account the
low efficiency of conventional nebulizers in the neonatal population, this device
could be helpful in the nebulization of other medical substances (bronchodilators,
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steroids, antibiotics, etc.). To that end, a multidisciplinary group has been assem-
bled in the last years formed by the Cruces University Hospital-BIOEF (Basque
Foundation for Health Innovation and Research), the Department of Nautical Sci-
ence and Marine Systems and the Nuclear Engineering and Fluid Mechanics De-
partment (UPV/EHU, University of the Basque Country).
Therefore, working in this direction and after evaluating all the different tech-
niques that are able to administer surfactant in a non-invasive way and the research
carried out in this field, it has been concluded that the combination of surfactant
in aerosol form along with the application of CPAP would be an optimal choice.
It has been observed that most of the current devices generate extracorporeal
aerosols, leading to low lung deposition values. For that reason, they started
to consider alternatives to generate an intracorporeal aerosol, as the inhalation
catheter studied deeply by Goikoetxea et al. [88, 98] both experimentally and nu-
merically with CFD techniques. Their study demonstrated the feasibility of this
device to deliver large amounts of surfactant and PFC to the lungs and provided
the basis to design a new specific device to treat the RDS in preterm infants.
The motivation of the current thesis is to design and manufacture a novel
nebulizer prototype and to evaluate the feasibility to generate droplets with po-
tential to be delivered in the supraglottic region. Additionally, a numerical model
is developed and validated with experimental data to facilitate further parametric
studies of optimal nebulizers in preterm babies with RDS.
1.7 Hypotheses
Two hypotheses have been considered in the development of this research. On
the one hand, it is argued that the non-invasive intracorporeal administration
of nebulized surfactant can be combined with a non-invasive ventilatory support
such as CPAP. The nebulizer prototypes proposed in this thesis are intended to
be placed in the supraglottic region, bypassing the upper airways, and directly
atomizing into the pharynx, avoiding the need for intubation and making them
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compatible with the use of CPAP.
On the other hand, it is argued that once the surfactant reaches the third
generation of the airways, and even to the trachea, it is easily distributed to the
more distal generations. This is due to the high viscosity of the surfactant and
the ability to spread once deposited on the walls. Therefore, a good distribution
through the lungs is ensured once the surfactant reaches the trachea.
1.8 Objectives
The main goal of this thesis is the design and development of a novel nebulizer
prototype able to generate aerosols to be inhaled by preterm infants. The specific
objectives that have been set to achieve this goal are the following:
• Characterization of the aerosol obtained with an inhalation catheter IC-1.1
by means of experimental measurements.
• Development of a numerical model with CFD tools of the aerosol produced
with the inhalation catheter IC-1.1.
• Validation of the CFD numerical model with experimental data.
• Study the feasibility of additive manufacturing techniques to fabricate a
prototype able to generate a nebulization process.
• Design a prototype allowing the aerosol generation and offering potential to
drug delivery without the need of intubation.
• Manufacture a nebulizer prototype with additive manufacturing techniques.
• Characterization of the aerosol obtained with the prototypes manufactured
by means of experimental measurements.
• Discuss the feasibility and limitations of the prototypes manufactured after
analyzing the experimental results obtained.
• Establish guidelines to optimize the design of the nebulizer prototype to
improve the aerosol characteristics, the distal pressure values and the
• Design a pressure control system able to control the liquid administration
velocity and the pressure applied throughout the prototype.
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1.9 Methodology
The methodology followed to complete these objectives consists in the application
of CFD techniques to develop a numerical model able to characterize the aerosol
particle size distribution, the design and manufacturing of optimized nebulizer
prototypes and the execution of experimental measurements (See Figure 1.9).
Figure 1.9: Flow chart of the methodology used.
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1.10 Contents and Structure of the Thesis
The current thesis has been structured with the following chapters:
• CHAPTER 1: Introduction. It contains a description of the RDS and
the current medical treatment, that involves the surfactant replacement ther-
apy and the use of ventilatory support. New minimally invasive surfactant
therapies (MIST) are described and, in particular, the surfactant nebuliza-
tion with new aerosol devices. Finally, the use of CFD tools in the modeling
of human respiratory airways and pharmaceutical aerosols is described.
• CHAPTER 2: Aerosol Model with Inhalation Catheter. This chap-
ter presents an experimental and numerical model of the aerosol produced by
means of the inhalation catheter IC-1.1 (Aeroprobe, Trudell Medical Interna-
tional). The nebulization produced with three different compounds is stud-
ied: distilled water (H2Od) and two perfluorocarbons (PFC); perfluorodeca-
lyn (PFD) and FC75. An Aerodynamic Particle Sizer (APS) spectrometer
is used to carry out the particle size characterization of the droplets gener-
ated with the IC-1.1. Additionally, a 2D axisymmetrical numerical model is
developed with CFD techniques and validated with experimental data.
• CHAPTER 3: Nebulizer Prototype Design. This chapter, initially,
describes the use of additive manufacturing techniques in medical applica-
tions, the main technologies currently used and their characteristics. Then,
two nebulizer prototypes are designed and manufactured by means of the
PolyJet technology. Experimental measurements are taken with the APS
for both prototypes using H2Od, PFD and FC75. Finally, the droplet size
and mass characterization results are compared and discussed.
• CHAPTER 4: Optimization of Nebulizer Prototype. This chapter
contains guidelines to optimize the design of the nebulizer prototype. Some
modifications in the design of the prototypes are included with the aim of
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improving the nebulization process and to reduce the pressure at the distal
end of the prototypes. New prototypes are manufactured and experiments
are made to control the distal pressure and the nebulization velocity.
• CHAPTER 5: Conclusions and Future Work. To conclude, this chap-
ter presents the main conclusions of the research work carried out and pro-
poses future lines and considerations to advance in the investigation of this
subject area.
Additionally, two Appendices have been introduced:
• APPENDIX A: Nebulizer Prootypes Designs. It contains all the
drawings corresponding to the nebulizer prototypes designed throughout this
thesis.
• APPENDIX B: Publication and Conferences. The results and conclu-
sions obtained in the current thesis have been published in two JCR indexed
journals: International Journal of Environmental Research and Public Health
(IF 2.468) and Pharmaceutics (IF 4.773). In addition, two contributions were
presented in two different international conferences.
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CHAPTER 2
AEROSOL MODEL WITH
INHALATION CATHETER
2.1 Experimental Model
This section presents, initially, the inhalation catheter used for the aerosol genera-
tion, the compounds studied and the experimental setup installed to measure the
mass and size particle distribution. Finally, the experimental results obtained are
presented for each compound and pressure studied.
2.1.1 Inhalation Catheter
The inhalation catheter IC-1.1 (Aeroprobe, Trudell Medical International) has
been used to model the aerosol generation. This type of catheter, which has already
been tested in different studies [98, 99], allows the generation of intracorporeal
aerosols avoiding the deposition of aerosol droplets in the nasopharyngeal region.
Additionally, it can be placed in a non-invasive manner and does not involve
an increase in the temperature of the compound to be nebulized, as opposed as
33
Chapter 2. AEROSOL MODEL WITH INHALATION CATHETER
vibrating mesh nebulizers. The total length of the IC-1.1 is 1 meter and consists
of a central lumen, where the liquid to be nebulized is delivered, and six outer
lumens where compressed air is dispensed, as illustrated in Figure 2.1.
Figure 2.1: Inhalation catheter (IC 1.1) with a cross section detail of the distal
end.
The diameter of these lumens becomes smaller as it approximates to the
catheter tip. The proximal diameter of both central and outer lumens is 330
µm, while in the catheter tip the diameter corresponds to 68.6 µm and 66.4 µm
for the central and outer lumens, respectively. The high air velocity produced due
to the diameter reduction, along with the closeness of the lumens, leads to the
nebulization of the liquid.
2.1.2 Compounds Nebulized
Three different compounds have been used in order to analyze the aerosol gener-
ation with the IC-1.1. Distilled water (H2Od) and two different perfluorocarbons
(PFC); perfluorodecalyn (PFD; C10F18, F2 Chemicals Ltd., Lancashire, UK) and
FC75 (C8F16O, Fluorinert, 3M, Neuss, Germany). Their properties can be seen
in Table 2.1. Distilled water is used for drug dilution and the aerosolization of
aqueous medications whereas the biophysical properties of PFCs have shown to
improve oxygenation and to reduce lung injury in cases of severe respiratory in-
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sufficiency, as studied by Guo et al. [100]. Partial liquid ventilation with PFCs
has been used in the experimental field and proven effective in the treatment of
various lung diseases in a wide range of animal models, reaching human clini-
cal trials [101]. The aerosol delivery of PFCs has been suggested as a promising
method over instillation to improve lung function [102]. Von der Hardt et al. [103]
compared different PFCs in surfactant-depleted rabbits showing their effectiveness
and suitability for aerosol treatment.
Parameter H2Od PFD FC75
Density (ρ) [g/ml] 0.99 1.95 1.78
Kinematic viscosity (υ) [cSt] 1.003 2.70 0.81
Surface tension (σ) [dyn/cm] 73 15 15
Table 2.1: Properties of H2Od and PFCs.
2.1.3 Experimental Setup
Figure 2.2 shows the experimental setup installed to measure the particle size
distribution of the aerosols generated with the IC-1.1. The mean aerodynamic di-
ameter (Da), the mass median aerodynamic diameter (MMAD) and the geometric
standard deviation (GSD) have been analyzed.
The aerosol parameters obtained with the IC-1.1 were measured with the help
of the Aerodynamic Particle Sizer (APS) spectrometer illustrated in Figure
2.3, which provides high-resolution measurements of aerosol droplets from 0.5 µm
to 20 µm. The distance between the catheter tip of the IC-1.1 and the inlet nozzle
of the APS was checked in order to obtain the average 1000 droplets/cm3 con-
centration recommended by the manufacturer. The APS uses a patented double-
crested optical system for unmatched sizing accuracy and, by means of two laser
beams, it generates a signal when a droplet passes through them (See Figure
2.4). The acceleration of droplets, that will be smaller for bigger droplets because
of their larger inertia, is obtained from the time between the peaks of the sig-
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Figure 2.2: Experimental setup used for the particle size characterization of the
droplets generated with the IC-1.1.
nal, also known as time-of-flight. Then, with the sphere calibration stored in the
spectrometer memory, the APS converts each time-of-flight measurement to its
corresponding aerodynamic particle diameter (Da), described as the diameter of
a spherical droplet with a density of a water droplet (1000 kg/m3) that has the
same settling velocity as the measured droplet.
Figure 2.3: Aerodynamic Particle Sizer (APS) Model 3321.
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Figure 2.4: (a) Aerodynamic Particle Sizer (APS) operation scheme, (b) detail
view with aerosol droplets crossing the overlapping beams and generating the
double-crested signal.
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The APS measures and classifies the droplets in four events according to
their aerodynamic diameter, as can be seen in Figure 2.5. The first one groups
the droplets with a diameter smaller than 0.5 µm, the second one classifies the
droplets that are in the spectrometer measuring range from 0.5 µm to 20 µm. The
third event considers those particles that cross the laser beams at the same time,
and the last event group droplets bigger than 20 µm.
Therefore, in order to have a sample measured accurately, it is important to
have most of the particles classified in the first two events and, above all, in the
second event where droplets from 0.5 µm to 20 µm are measured. In other words, it
is convenient to obtain a negligible percentage at events three and four to consider
the measurement reliable, where particle coincidence and particles out of the range
of measurement are classified, respectively. All data and information captured by
the APS is recorded and visualized by the Aerosol Instrument Manager software.
Figure 2.5: Percentage of droplets classified in each event for one sample.
The air pressure controller shown in Figure 2.6 (LABneb, Trudell Medical
International), with an operating range of 0-7 bar, has been used to provide com-
pressed air to both the small piston placed within the liquid chamber and to the
side connection of the IC-1.1.
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Figure 2.6: Air pressure controller.
Figure 2.7 shows the liquid chamber filled with the liquid desired to be nebu-
lized, the three-way valve to control the liquid distribution and the two connections
to deliver the liquid and the compressed air to the central and outer lumens of the
IC-1.1.
Figure 2.7: Distribution of compressed air to the piston of the liquid chamber and
to the side connection of the IC-1.1.
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The catheter has been aligned with the APS nozzle in the vertical direction to
obtain accurate measurements of the aerosols generated. Initially, due to the length
of the IC-1.1 and the small dimensions of the distal tip, the catheter presented
some alignment issues during the nebulization process. In order to avoid that, the
distal end of the catheter has been passed through a cylindrical plastic guide with
a drill of 1 mm, as can be observed in Figure 2.8.
Figure 2.8: Alignment of the IC-1.1.
2.1.4 Experimental Results
The characterization of the aerosols formed with the IC-1.1 was studied by means
of the Da, the MMAD and the GSD. The relationship between the aerodynamic
droplet diameter (Da) measured by the APS and the geometric droplet diameter
(Dg) is given by Equation 2.1.
Dg = Da
√
ρ0
ρ
(2.1)
where ρ0 is the unit density (1 g/cm3) and ρ the density of the compound to
be nebulized.
The MMAD measures the aerodynamic diameter (Da) at which 50% of the
aerosol mass is present in droplets below or above this value. Finally, the GSD is
a dimensionless number which gives an indication of the spread of sizes of droplets
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that form the aerosol. A GSD value below 1.2 indicates that the aerosol is formed
by droplets with the same or very nearly size (monodisperse aerosol) whereas a
value above 1.2 shows that the aerosol contains droplets of many different sizes
(heterodisperse aerosol) [76].
Different distances between the distal end of the catheter and the APS nozzle
were tested in order to obtain an aerosol with a concentration as close as possible
to the recommended value of 1000 droplets/cm3. In the case of H2Od, it was
found that the optimal distance was 42 cm. A sample time of 10 seconds was
set, recording five samples for each pressure and verifying that in each sample
most of the droplets were classified within the second event. Tables 2.2 and 2.3
show the results nebulizing H2Od at four different driving pressures from P=4
bar to P=6 bar. It was observed a smooth proportional increase in the Da value
with the driving pressure, from 4.06±0.05 µm (4 bar) to 4.84±0.05 µm (6 bar).
The MMAD values varied between 10-11 µm and in all cases the IC-1.1 produced
heterodisperse aerosols, with a GSD between 1.89±0.06 (6 bar) and 2.18±0.03 (4
bar).
H2Od P=4 bar (h=42cm) H2Od P=4.5 bar (h=42cm)
Sample Da
(µm)
MMAD
(µm)
GSD Sample Da
(µm)
MMAD
(µm)
GSD
11 4.00 10.3 2.20 16 4.55 10.8 2.09
12 4.09 10.3 2.19 17 4.24 10.2 2.14
13 4.08 10.1 2.15 18 4.33 10.6 2.16
14 4.12 9.89 2.14 19 4.51 10.5 2.06
15 4.01 10.2 2.21 20 4.67 10.9 2.08
MEAN 4.06 10.16 2.18 MEAN 4.46 10.60 2.11
SD 0.05 0.17 0.03 SD 0.17 0.27 0.04
Table 2.2: H2Od experimental results with driving pressures of P=4 bar and P=4.5
bar.
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H2Od P=5 bar (h=42cm) H2Od P=6 bar (h=42cm)
Sample Da
(µm)
MMAD
(µm)
GSD Sample Da
(µm)
MMAD
(µm)
GSD
21 4.54 10.4 2.09 26 4.79 11.1 2.00
22 4.77 11.1 2.08 27 4.88 10.7 1.89
23 4.76 11.0 2.08 28 4.86 10.5 1.86
24 4.83 11.1 2.04 29 4.89 10.1 1.84
25 4.91 11.1 1.98 30 4.79 10.4 1.87
MEAN 4.76 10.94 2.18 MEAN 4.84 10.56 1.89
SD 0.14 0.30 0.03 SD 0.05 0.37 0.06
Table 2.3: H2Od experimental results with driving pressures of P=5 bar and P=6
bar.
Both PFC compounds, PFD and FC75, were tested at driving pressures of 4-5
bar, as shown in Tables 2.4 - 2.7. The optimal distance to get a concentration
close to the 1000 droplets/cm3 recommended was 60 mm and 52 mm, for PFD
and FC75 respectively. Initially, for FC75, measurements were taken at higher
distances. However, a very low droplet concentration was observed that could be
explained by the high volatility of the compound. For both PFCs, the Da value
decreased when the driving pressure was increased from 4 bar to 5 bar at the
optimal distance (See Tables 2.6-2.7). From 4.33±0.03 µm to 4.18±0.03 µm with
PFD and from 2.45±0.01 µm to 2.28±0.02 µm with FC75. Regarding the MMAD,
PFD showed more stable values with an increase in the driving pressure applied
to the IC-1.1, from 7.21±0.02 µm (4 bar) to 7.14±0.05 µm (5 bar). However, with
FC75, the MMAD value showed a significantly decrease with an increase in the
driving pressure, from 10.01±0.44 µm (4 bar) to 4.83±0.17 µm (5 bar).
Additionally, measurements at 30 mm and 46 mm were taken for the PFD
compound to study the influence of the distance between the distal tip of the IC-
1.1 and the APS inlet nozzle and to compare the results with the numerical model
presented in the next section.
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PFD P=4 bar (h=30mm) PFD P=5 bar (h=30mm)
Sample Da
(µm)
MMAD
(µm)
GSD Sample Da
(µm)
MMAD
(µm)
GSD
1 3.96 7.07 1.99 6 3.97 6.27 1.80
2 4.13 6.61 1.76 7 3.99 6.33 1.82
3 4.09 6.46 1.73 8 3.98 6.32 1.82
4 4.12 6.55 1.74 9 3.93 6.21 1.82
5 4.09 6.50 1.74 10 3.96 6.36 1.84
MEAN 4.08 6.64 1.79 MEAN 3.97 6.30 1.82
SD 0.07 0.25 0.11 SD 0.02 0.06 0.01
Table 2.4: PFD experimental results at h=30mm with driving pressures of P=4
bar and P=5 bar.
PFD P=4 bar (h=46mm) PFD P=5 bar (h=46mm)
Sample Da
(µm)
MMAD
(µm)
GSD Sample Da
(µm)
MMAD
(µm)
GSD
11 4.24 7.37 2.03 16 4.18 6.84 1.85
12 4.31 7.46 2.06 17 4.22 7.14 1.94
13 4.24 7.44 2.03 18 4.20 7.24 2.01
14 4.26 7.45 2.04 19 4.16 7.30 2.07
15 4.31 7.48 2.02 20 4.16 7.37 2.09
21 4.28 7.44 2.11
22 4.10 6.83 1.85
23 4.13 6.91 1.86
MEAN 4.27 7.44 2.04 MEAN 4.22 7.13 1.97
SD 0.04 0.04 0.02 SD 0.08 0.24 0.11
Table 2.5: PFD experimental results at h=46mm with driving pressures of P=4
bar and P=5 bar.
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PFD P=4 bar (h=60mm) PFD P=5 bar (h=60mm)
Sample Da
(µm)
MMAD
(µm)
GSD Sample Da
(µm)
MMAD
(µm)
GSD
24 4.30 7.24 1.95 29 4.18 7.20 1.99
25 4.36 7.22 1.89 30 4.22 7.12 1.95
26 4.30 7.19 1.93 31 4.20 7.17 1.95
27 4.33 7.21 1.91 32 4.16 7.10 1.93
28 4.35 7.20 1.91 33 4.16 7.09 1.94
MEAN 4.33 7.21 1.92 MEAN 4.18 7.14 1.95
SD 0.03 0.02 0.02 SD 0.03 0.05 0.02
Table 2.6: PFD experimental results at h=60mm (optimal distance) with driving
pressures of P=4 bar and P=5 bar.
FC75 P=4 bar (h=52mm) FC75 P=5 bar (h=52mm)
Sample Da
(µm)
MMAD
(µm)
GSD Sample Da
(µm)
MMAD
(µm)
GSD
1 2.47 10.50 1.70 6 2.28 5.06 1.62
2 2.45 10.10 1.69 7 2.32 4.89 1.62
3 2.44 10.30 1.70 8 2.27 4.88 1.60
4 2.45 9.73 1.68 9 2.27 4.60 1.60
5 2.43 9.42 1.68 10 2.27 4.74 1.60
MEAN 2.45 10.01 1.69 MEAN 2.28 4.83 1.61
SD 0.01 0.44 0.01 SD 0.02 0.17 0.01
Table 2.7: FC75 experimental results at h=52mm (optimal distance) with driving
pressures of P=4 bar and P=5 bar.
44
2.2. Numerical Model
Figure 2.9 summarizes the D¯a and MMAD results obtained with the IC-1.1 for
the three compounds studied, H2Od, PFD and FC75.
(a) (b)
Figure 2.9: (a) D¯a and (b) MMAD results obtained at the optimal distance for each
compound and driving pressure. Values are given as mean ± standard deviation.
These experimental results were used subsequently to validate the numerical
model presented in Section 2.2 of the current chapter. Furthermore, measurements
at nozzle level (h=0) were taken to define the initial conditions of the injectors
that will represent the population of droplets in the numerical model. Even though
the average droplet concentration measured at this point was higher than the
recommended, the vast majority of them were grouped in the second event, which
classifies the droplets within the measurement range from 0.5 µm to 20 µm.
2.2 Numerical Model
In addition to the experimental model, CFD tools have been used to study more in
detail the aerosol characteristics produced with the IC-1.1. This numerical model,
which has been validated with the experimental data obtained in the previous
section, will be helpful in the study of future nebulizer prototypes as well as to
carry out parametric studies to achieve the optimal aerosol delivery in preterm
babies with RDS. The CFD analysis to study the flow behavior involves three
main elements: pre-processor, solver and post-processor (See Figure 2.10).
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The pre-processing consists in the definition of the geometry of the region of
interest (computational domain), the discretization of this domain into a number
of smaller, non-overlapping subdomains (mesh generation) and the specification of
appropiate boundary conditions. Then, the solver proceeds to the discretization
of the differential equations of the flow by means of the Finite Volume Method
(FVM) along with the definition of interpolation schemes. In the case of unsteady
flows, as the aerosols developed with the IC-1.1, a temporal discretization is also
necessary as well as a parcel discretization which represents the discrete phase. The
resolution of the numerical model requires an iterative process and the convergence
of the solution is commonly assesed by progressively tracking the imbalances of
the algebraic equations through each iteration step. The post-process involves
the quantification of the results and their validation with the experimental results
obtained previously.
Figure 2.10: CFD analysis framework and the interconnectivity functions of the
three main elements involved.
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CFD tools have emerged as a viable approach for either industrial and research
applications as a result of the constant improvement of digital workstations and
computational resources. With the introduction of new solvers and theoretical
physics models, CFD techniques allow to study alternative designs under a wide
range of parameters and conditions. In the current thesis, the CFD commercial
code STAR-CCM+ v.11.06 [104] has been used to develop all the steps of the
numerical model. An Intel Xeon E5-2630 v3 2.4 GHz CPU computer with 32 GB
RAM has been used to run all the simulations.
2.2.1 Computational Domain and Boundary Conditions
The first step in any CFD analysis is the definition and creation of the computa-
tional domain. The Lagrangian multiphase simulations that are needed to simulate
an aerosol of these characteristics involve a high computational cost due to the
solution of the trajectory of each of the discrete droplets of the aerosol. For that
reason, it has been assumed an axisymmetrical computational domain with
an outer ring instead of the six original lumens, as illustrated in Figure 2.11.
Figure 2.11: (a) Cross section of the IC-1.1 tip and (b) the assumption defined for
the generation of the axisymmetrical computational domain.
The width of this ring was calculated in order to have the same area of the six
original outer lumens and, therefore, to supply the same air mass flow.
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Original outer lumen area
pi · d2
4 =
pi · 66.42µm
4 = 3462, 789 µm
2
With 6 lumens: 3462, 789 µm
2
lumen
· 6 lumens = 20776,73 µm2
where d is the diameter of each of the six outer lumens in the distal tip.
Assumed ring area
pi · [(2 · blcen) + d]2
4 =
pi · (225.2 + 66.4)2µm
4 = 66782, 845 µm
2
pi · [(2 · blcen)− d]2
4 =
pi · (225.2− 66.4)2µm
4 = 19805, 731 µm
2
66782, 845 µm2 − 19805, 731 µm2 = 46977,11 µm2
where blcen, which defines the position of the outer lumen, has been maintained
with respect to the original geometry. Then, to calculate the ring width keeping
the original total outer lumen area:
pi · (225, 2 + x)2
4 −
pi · (225.2− x)2
4 = 20776, 73 µm
2
x = 29, 3669 µm ≈ 29,4 µm = ring width
Thus, the ring, defined as (r2 − r1) has a width of 29,4 µm, where
r1 = 112, 6 µm− 29, 4 µm2 = 97, 9 µm
r2 = 112, 6 µm+
29, 4 µm
2 = 127, 3 µm
Figure 2.12 shows the original geometry of the IC-1.1 and how it has been
transformed in order to replace the six outer lumens with an outer ring of the
same area.
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Figure 2.12: Transformation of the six outer lumens into an outer ring to carry
out the numerical study.
The computational domain consists of the last 2 mm of the IC-1.1 and the
downstream region beyond the catheter tip, as shown in Figure 2.13. The opti-
mal distance used in the experimental setup to obtain the average recommended
particle concentration with the APS has been used to define the outlet boundary
condition, which has been located at L=60 mm and L=52 mm for PFD and FC75,
respectively.
Figure 2.13: Computational domain and boundary conditions.
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An air mass flow rate of m˙air=1.1344·10−5 kg/s, previously measured with a
pressure of 4 bar in the study of Goikoetxea et al. [98], and of m˙air=1.14766·10−5
kg/s with a pressure of 5 bar has been used to define the inlet boundary condition.
In addition, an axisymmetrical boundary condition has been fixed along the central
axis and an atmospheric pressure outlet condition has been set for the downstream
boundaries.
For the representation of the discrete phase droplets, ten droplet injectors have
been created and uniformly distributed through an injection line, whose length is
equal to the radius of the central lumen of the IC-1.1 (34.3 µm). The ten injections
have been defined using the experimental results obtained with the APS at the
nozzle level (h=0) and interpolating the data from the 52 intervals of the APS
sample chosen. They were set at a distance of 2 mm from the catheter tip as an
approximated value between the APS nozzle, where the catheter tip was placed to
take the measurements, and the APS laser beams which measure the distribution
of the droplets.
The non-slip condition has been established on the walls. According to this
condition, the flow adjacent to the wall has the same velocity as the wall, in this
case null. The temperature of the walls has been set to 293K and a turbulence
intensity of 0.07 has been defined, based on the hydraulic diameter (Dh) calculated
as the difference of the outer and inner diameter of the ring.
I = 0.16 (ReDh)−1/8 (2.2)
Other possible interaction mechanisms, which have not been considered in the
current numerical model, are the collision of the droplets as well as the formation
of a liquid film.
The velocity of the droplets injected through the injection line has been set
equal to the velocity of the airflow at this position. The droplet mass and size
distribution values of these initial injections, obtained from the experimental mea-
surements, are defined in Table 2.8 for each PFC compound.
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PFD FC75
INJ Dg (µm)
m˙ (kg/s)
Dg (µm)
m˙ (kg/s)
4 bar 5 bar 4 bar 5 bar
1 0.375 1.43 ·10−9 6.08·10−12 0.392 5.44·10−9 2.53·10−11
2 0.577 9.02·10−10 1.49·10−11 0.604 4.27·10−9 8.35·10−11
3 0.828 1.18·10−8 2.77·10−10 0.866 5.04·10−8 1.48·10−9
4 1.275 9.35·10−8 4.82·10−9 1.335 3.84·10−7 2.48·10−8
5 1.825 2.87·10−7 3.30·10−8 1.910 1.09·10−6 1.61·10−7
6 2.810 5.14·10−7 1.91·10−7 2.945 1.91·10−6 9.76·10−7
7 4.330 1.79·10−7 5.77·10−7 4.535 1.00·10−6 2.49·10−6
8 6.205 5.26·10−8 4.64·10−7 6.495 2.46·10−7 1.93·10−6
9 9.555 1.21·10−7 1.44·10−7 10.000 2.57·10−7 5.52·10−7
10 14.19 2.31·10−8 1.72·10−8 14.850 7.81·10−8 6.37·10−8
Total mass
flow rate
1.28·10−6 1.43·10−6 5.03·10−6 6.20·10−6
Table 2.8: Droplet initial conditions for PFD and FC75 compounds obtained from
experimental measurements.
2.2.2 Mesh Generation
The mesh generation represents one of the most important steps during the pre-
process part before running the numerical solution. The CFD code requires the
division of the computational domain in smaller subdomains in order to solve the
flow physics. In this thesis, polygonal cells have been used with a mesh refinement
in the region close to the catheter tip and all along the central axis, as shown in
Figure 2.14. To ensure that the numerical solution is independent of the mesh
size, a mesh dependency study has been carried out following the procedure of
Richardson’s extrapolation [105]. Three different mesh levels were created (coarse,
medium and fine) with mesh sizes h3, h2 and h1, respectively. The mesh refinement
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ratio is given by the Equation 2.3.
Mesh refinement ratio = r = h2
h1
(2.3)
The axial velocity in a point at the outlet was the parameter chosen to control
the study. Tables 2.9 - 2.11 show the results obtained for the FC75 compound
with a driving pressure of 5 bar.
Mesh Number of cells vaxial(m/s)
M1 404.620 9.58
M2 196.107 9.41
M3 98.854 8.92
Table 2.9: Axial velocity values in the chosen point for each mesh level.
The extrapolated axial velocity value was calculated by Equation 2.4
(vaxial)h=0 = (vaxial)1 +
(vaxial)1 − (vaxial)2
rp − 1 (2.4)
where p is the order of convergence, defined as:
p =
ln
(
(vaxial)3−(vaxial)2
(vaxial)2−(vaxial)1
)
ln2 (2.5)
The discretization error of the computed solution was calculated using the grid
convergence index (GCI) with the three levels of mesh previously defined (See
Equations 2.6 - 2.7). A small value of GCI indicates that the solution is within
the asymptotic range of convergence [106].
GCI12 = Fs
∣∣∣(vaxial)1 − (vaxial)2(vaxial)1 ∣∣∣
rp − 1 · 100
GCI23 = Fs
∣∣∣(vaxial)2 − (vaxial)3(vaxial)2 ∣∣∣
rp − 1 · 100
(2.6)
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GCI23
rp ·GCI12 ≈ 1 (2.7)
Vaxial(m/s) Error (%)
(vaxial)h=0 (m/s) 9.67
M1 9.58 0.93
M2 9.41 2.69
M3 8.92 7.76
Table 2.10: Errors obtained for each mesh level.
Domain
GCI12 (%) 1.21
GCI23 (%) 3.65
GCI23
rp ·GCI12 (-) 1.05
Table 2.11: Grid Convergence Index (GCI) results.
Figure 2.14: Mesh generated by means of polygonal cells and with a mesh refine-
ment all along the central axis.
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The mesh level M1, with 404.620 cells, was chosen to create the numerical
model taking into consideration the error obtained for each mesh level, and that
the GCI23/rp ·GCI12 relation was close to 1 (See Tables 2.10 - 2.11).
2.2.3 Physics Models
This section describes the physics models that have been introduced to define the
numerical model. The aerosol produced with the IC-1.1 generates a multiphase
flow with a continuous phase (air flow) and a discrete phase (PFC droplets).
The Eulerian approach has been used to define the continuous phase whereas
the Lagrangian approach has been used to define the discrete phase formed by
the PFC droplets. Initially, the governing equations for the continuous phase are
described along with the turbulence modeling. Then, the discrete phase modeling
is discussed, with the definition of the Lagrangian multiphase model employed,
the governing equations for the discrete phase, the turbulent dispersion and the
interaction between the continuous and dispersed phase.
2.2.3.1 Governing equations for the continuous phase
The Eulerian approach has been used for the resolution of the continuous phase,
which consists of analyzing the airflow in a control volume or flow domain. The
main variables that arise when solving a continuous flow are the velocity fields (u,
v, w) and pressure (P). In this specific case, the velocities reached by the IC-1.1
in the distal region of the catheter make it necessary to consider the effects of air
compressibility and, therefore, consider that the density of the fluid is function
of temperature and pressure. Hence, along with pressure and velocity new flow
variables appear as the temperature (T ), density (ρ), specific internal energy (e)
and specific enthalpy (h).
These flow variables appear in the Navier-Stokes equations, which describe
the motion of fluid droplets. For motion in a compressible medium, the CFD
code must solve the governing equations of conservation of mass, momentum and
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energy (See Equations 2.8 - 2.10) [107].
∂ρ
∂t
+ ∂(ρui)
∂xi
= 0 (2.8)
∂(ρui)
∂t
+ ∂(ρuiuj)
∂xj
= − ∂P
∂xi
+ ∂tij
∂xj
+ F (2.9)
∂
∂t
[
ρ
(
e+ 12uiui
)]
+ ∂
∂xj
[
ρuj
(
h+ 12uiui
)]
= ∂
∂xj
(uitij) +
∂
∂xj
(
κ
∂T
∂xj
)
+Q
(2.10)
where κ is thermal conductivity, tij is the instantaneous viscous stress sensor
and F and Q are the terms that model the exchange of energy and momentum
with the discrete phase. The constitutive relation between stress and strain rate
for a Newtonian fluid is given by Equation 2.11.
tij = 2µsij − 23µ
∂uk
∂xk
δij (2.11)
where sij is the instantaneous strain-rate tensor, given by Equation 2.12.
sij =
1
2(
∂ui
∂xj
+ ∂uj
∂xi
) (2.12)
Considering the air flow an ideal gas, three equations of state have been in-
cluded in the Navier-Stokes equations that relate the thermodynamic variables,
as shown in Equations 2.13 - 2.15. Thus, a system of eight equations with eight
unknown variables is obtained.
P = ρRT (2.13)
e = cvT (2.14)
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h = cpT (2.15)
where R is the ideal gas constant, cv the specific heat for constant volume and
cp the specific heat for constant pressure.
All these equations have to be adapted to take into account the flow turbulence,
according to the way chosen to carry out the modeling. Thus, new equations are
also necessary to solve the new turbulent variables that will appear.
2.2.3.2 Turbulence modeling
The fluid regime depends on the value of Reynolds number (Re), a dimensionless
number which is defined as the ratio of inertial forces to viscous forces, as shown
in Equation 2.16.
Re = vL
ν
= inertial forcesviscosity forces (2.16)
where L is a characteristic linear dimension, υ is the characteristic velocity of
the object relative to the fluid and ν is the kinematic viscosity.
At larger Reynolds numbers, the fluid’s inertia overcomes the viscous stresses,
and the laminar motion becomes unstable. Large velocity and pressure fluctuations
appear and the motion becomes inherently three dimensional and unsteady. When
this occurs the motion is described as turbulent [108].
Different methodologies are used to resolve a turbulent flow. The most accurate
option is the Direct Numerical Simulation (DNS), which means a complete
three dimensional and time-dependent solution of the Navier-Stokes and continuity
equations. All scales of turbulence are resolved without modeling. Another option
is the Large Eddy Simulation (LES), where the largest eddies are resolved and
the smallest eddies are modeled. These two methodologies achieve very accurate
solutions, even though their computational cost is very high, especially in DNS.
Any time and space dependent flow variable (φ(x, t)) can be written as the
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sum of an average (φ¯(x)) and a fluctuation (φ′(x, t)), as shown in Equation 2.17.
φ(x, t) = φ¯(x) + φ
′
(x, t) (2.17)
This decomposition yields a set of equations governing the average flow field,
called the Reynolds Averaged Navier Stokes Equations (RANS). With a
RANS approach all turbulent scales are modeled and, therefore, the computer
demands decrease substantially. RANS-models can be divided into two major cat-
egories, the Eddy Viscosity Models (EVM) and the Reynolds Stress Transport
Models (RSTM). The RSTM use more transport equations and achieve more ac-
curate results, dealing with the isotropy of turbulence and the extra strains. How-
ever, the EVM demands less computational cost, they are robust and even though
they do not calculate with precision the Reynolds stresses they predict quite well
the average values of the variables. The most common EVM is known as the
Boussinesq approximation, which considers that it exists an analogy between the
molecular gradient-diffusion process and turbulent motion.
−ρ¯τij = 2µt
(
Sij − 13
∂u˜
∂xk
δij
)
− 23 ρ¯kδij (2.18)
Sij =
1
2
(
∂u˜i
∂xj
+ ∂u˜j
∂xi
)
(2.19)
where µt is the turbulent eddy viscosity and Sij is the mean strain rate tensor
given by Equation 2.19.
While some simpler models rely on the concept of mixing length to model
the turbulent viscosity in terms of mean flow mean quantities, the EVM solve
additional transport equations for scalar quantities that enable the turbulence
to be derived. In this thesis, the EVM with two transport equation have been
chosen to define the turbulence modeling by means of the Realizable K-Epsilon
Two-Layer turbulence model.
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k- turbulence model
The k- turbulence model is a two-equation model that solves transport equa-
tions for the turbulent kinetic energy (k) and the turbulent dissipation rate ()
in order to determine the turbulent eddy viscosity. It relates the turbulent eddy
viscosity µt, the turbulent kinetic energy k and the dissipation rate  by means of
Equation 2.20.
µt = ρ Cµ
k2

(2.20)
The Realizable k- model contains a new transport equation for the turbulent
dissipation rate . Adittionally, a critical coefficient of the model Cµ is expressed
as a function of mean flow and turbulence properties, rather than assumed to be
constant as in the standard k- model. Equations 2.21 - 2.22 represent the trans-
port equations for the turbulent kinetic energy (k) and the turbulent dissipation
rate (), respectively.
∂
∂t
(ρk) + ∂
∂xi
(ρkui) =
∂
∂xj
[(
µ+ µt
σk
)
∂k
∂xj
]
− ρ− YM +Gk (2.21)
∂
∂t
(ρ) + ∂
∂xj
(ρuj) =
∂
∂xj
[(
µ+ µt
σ
)
∂
∂xj
]
+C1

k
G − C2 f2 ρ
(

T
− 0
T0
) (2.22)
with the following coefficients values:
C1 = 1.44; C2 = 1.9; Cµ = 0.09; σk = 1.0; σ = 1.2
YM and Gk are production terms to represent the compressibility modification
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and turbulent production, respectively, whereas T is the large-eddy time scale.
Gk = 2µtSijSij (2.23)
YM =
CMk
c2
(2.24)
T =
k

(2.25)
where c is the speed of sound and CM is a coefficient value (CM = 2)
0 is the ambient turbulence value in the source terms that counteracts turbu-
lence decay. The possibility to impose an ambient source term also leads to the
definition of a specific time-scale T0 that is defined as:
T0 = max
(
k0
0
, Ct
√
v
0
)
(2.26)
where Ct is a model coefficient that for the k- turbulence model takes a value
of Ct=1.
The transport equation for the turbulent kinetic energy (k) is insensitive, by
construction, to stabilizing and destabilizing effects usually associated with strong
streamline curvature and frame rotation. These effects can be incorporated by
using a curvature correction factor, which alters the turbulent kinetic energy pro-
duction term according to the local rotation and vorticity rates. The curvature
correction factor fc is calculated as:
fc = min
(
Cmax,
1
Cr1 (|η| − η) +
√
1−min (Cr2 , 0.99)
)
(2.27)
Wall treatment
Walls are a source of vorticity and, therefore, an accurate predicition of flow
and turbulence parameters across the wall boundary layer is essential. Close to the
wall the mean flow velocity (U ) only depends on the distance y from the wall, the
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fluid density ρ and viscosity µ and the wall shear stress τw. Dimensional analysis
shows the so-called law of the wall and contains the definitions of two important
dimensionless groups, u+ and y+ (See Equation 2.28) [109].
u+ = U
uτ
= f
(
ρuτy
µ
)
= f(y+) (2.28)
where uτ is the so-called friction velocity defined as:
uτ =
√
τw
ρ
(2.29)
The inner region of the boundary layer can be divided into three sublayers. The
viscous sublayer is the fluid layer in contact with the wall, which is dominated by
viscous effects and is almost laminar. The buffer layer, a transitional layer where
viscous and turbulent effects are equally important and the log-law layer, mainly
affected by turbulent effects (See Figure 2.15). The non-dimensional wall distance
y+, given by Equation 2.30, is used to define the extents of the sublayers.
y+ = uτy
ν
(2.30)
Two types of wall laws are used in STAR-CCM+. Standard wall laws, used
with high − y+ wall treatments and blended wall laws used with all − y+ wall
treatments, which include a buffer region that smoothly blends the laminar and
turbulent profiles together.
Two-layer approach
The two-layer approach, first suggested by Rodi [110], is an alternative to the
low Reynolds number approach that allows the k- model to be applied in the
viscous-affected layer (including the viscous sub-layer and the buffer layer). In
this approach, the computation is divided into two layers. In the layer next to
the wall, the turbulent dissipation rate () and the turbulent viscosity (µt) are
specified as functions of wall distance. The  values specified in the near-wall
layer are blended smoothly with the values computed from solving the transport
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Figure 2.15: Subdivisions of the near-wall treatment. Source: STAR-CCM+
equation far from the wall. The equation for the turbulent kinetic energy (k) is
solved across the entire flow domain. For the two-layer models the dissipation rate
near the wall is prescribed as:
 = k
3/2
l
(2.31)
where l is a length scale function that is calculated depending on the model
variant. The CFD code used provides three variants of two-layer models (Wolfstein
model, Norris-Reynolds model and Xu model). In this thesis, the Wolfstein two-
layer model [111] has been used where the length scale function (l) is defined by
means of Equation 2.32.
l = cld
[
1− e
(
−Red2cl
)]
(2.32)
cl = 0.42 C−3/4µ (2.33)
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2.2.3.3 Discrete phase modeling: Lagrangian multiphase model
Multiphase flows can be classified into two categories: stratified flows, such as free
surface flows or annular film flow in pipes and dispersed flows such as droplet flows
as the aerosol generated by means of the IC-1.1.
STAR-CCM+ provides different models depending on the characteristics of the
multiphase flow. The Volume-of-fluid (VOF) model is designed to capture the
interface between two immiscible fluids and, therefore, is suitable for multiphase
flows where two fluids are clearly and sharply separated, which is not the case of
the the dispersed flow generated by the IC-1.1.
For dispersed flows, it can be used either the Lagrangian multiphase model
(LMP) or the Eulerian multiphase model (EMP). The EMP considers the
droplets in terms of concentration (volume fraction) and averaged velocity. This
model is more economical than the LMP, particularly for flows with high droplet
concentrations. This model is based on a Eulerian-Eulerian formulation where
each phase has its own set of conservation equations. Phases are considered to be
mixed on length scales smaller than the length scales resolved by the grid, and
coexist everywhere in the flow domain. This model is suitable to flows where each
phase can be considered continuously mixed, for instance, a cloud of sand that is
transported by wind, bubbles moving inside liquids or two liquids in a mixer or
separator.
The LMP solves the trajectories of each droplet which is assumed to be spher-
ical and smaller than the cell size. This model allows to track the movement of
individual droplets in fine detail. Each track is calculated based on the Lagrangian
formulation. In order to save computational time, all the droplets are grouped in
numerical parcels, each of them constituted of several non-interacting identical
droplets. A key assumption of this model is that the volume fraction of the La-
grangian phase in each cell has to be smaller than 40%. In the study of Goikoetxea
et al. [98] it was found that the volume of compound nebulized by the IC-1.1 was
less than 0.5% of total volume independently of the compound and pressure used.
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Therefore, it has been considered the LMP model as the most suitable choice to
create the numerical model of the aerosols produced with the IC-1.1.
2.2.3.4 Droplet equations of motion
The conservation equation of momentum for a droplet is written in the Lagrangian
framework. The change in momentum is balanced by surface and body forces that
act on the droplet. The equation of conservation of momentum for a material
droplet of mass mp is given by:
mp
dvp
dt
= Fs + Fb (2.34)
where vp denotes the instantenous droplet velocity, Fs is the resultant of the
forces that act on the surface of the droplet and Fb is the resultant of the body
forces.
Fs = FD + Fp + Fvm (2.35)
where FD is the drag force, Fp is the pressure gradient force and Fvm is the
virtual mass force.
Much of the work in aerosol science is based on two assumptions [112]: (1) The
droplet is assumed to be spherical, which is quite reasonable since such small liquid
droplets are spherical and (2) the droplet density is assumed to be much larger than
the surrounding fluid density. The second assumption (i.e. ρdroplet >> ρair) is
acceptable, since the densities of the compounds analyzed in the numerical study,
PFD and FC75, are between 1000-2000 times the air density (ρPFD = 1950kg/m3;
ρFC75 = 1780kg/m3) and, therefore, ρdroplet ∼ 103ρair. This assumption simpli-
fies the analysis since surface forces as Fp and Fvm become insignificant [113].
Therefore, the droplet force balance equation is reduced to:
mp
dvp
dt
= FD + Fb (2.36)
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The drag force (FD) acts on the droplet in a uniform pressure field when there
is no acceleration of the relative velocity between the droplet and the conveying
fluid, air in this case. The force is quantified by the drag coefficient through the
Equation 2.37.
FD =
1
2CDρApv
2
rel (2.37)
where CD is the drag coefficient of the droplet, ρ is the density of the continuous
phase, Ap is the projected area of the droplet and vrel is the relative velocity
between the droplet and the air.
The drag coefficient (CD) is a function of the small-scale flow features around
the individual droplets. These features are impractical to resolve spatially and the
usual practice is to obtain the drag coefficient from correlations, tipically derived
from experiment or theoretical studies. The CFD code provides different methods
for defining the drag coefficient depending on the nature of the dispersed phase. In
this thesis, the Schiller-Naumann correlation [114] has been used, which is suitable
for the spherical liquid droplets generated by means of the IC-1.1.
CD =

24
Red
(
1 + 0.15Re0.687d
)
Red ≤ 103
0.44 Red > 103
(2.38)
where Red is the droplet Reynolds number.
Regarding the body forces (Fb), the gravity force has not been included in
the definition of the numerical study since it has been considered its effect as
negligible due to the high velocity values obtained at the distal end of the IC-1.1.
Other possible body forces, as Coulomb force, are not involved in this application.
Therefore, body forces have not been included in the definition of the discrete
phase.
64
2.2. Numerical Model
2.2.3.5 Turbulent dispersion
A droplet in a turbulent flow experiences a randomly-varying velocity field to which
it responds according to its inertia. This behaviour is modeled by a stochastic ap-
proach that includes the effect of instantaneous velocity fluctuations on the droplet.
According to Gosman and Ioannides [115], a droplet is assumed to pass through a
sequence of turbulent eddies as it traverses a turbulent flow field. Here, an eddy is
a local disturbance to the Reynolds-averaged velocity field. The droplet remains
in the eddy until either the eddy time-scale (τe) is exceeded, or the separation
between the droplet and the eddy exceeds the length scale of the eddy (le). A
droplet experiences an instantaneous fluid velocity v in each eddy, described as:
v = v¯ + v
′
(2.39)
where v¯ is the local Reynolds-averaged velocity and v′ is the eddy velocity
fluctuation, unique to each droplet. The latter is a normal (Gausian) deviate with
zero mean value and a standard deviation that comes from the eddy velocity scale
ue =
lt
τt
√
2
3 (2.40)
The turbulence model provides the length and time-scales of the turbulence, lt
and τt. Once generated, a single realization of v
′ continues to apply to a droplet
until its eddy interaction time is exceeded:
τl = min(τe, τc) (2.41)
The eddy time-scale measures the lifetime of the eddy, i.e., the maximum
interval over which a single realization of v′ remains valid. It can be related to the
diffusion of a passive scalar according to the underlying turbulence model, giving,
τe =
2µt
ρu2e
(2.42)
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The droplets can interact with the eddy for less than the eddy time-scale when
they have non-zero slip velocity, making it possible for the droplet to cross the
eddy and espape. The edDy transit time is defined only for material droplets
when the drag force is activated, in which case it is estimated from:
τc =
∞ τv ≤
le
|vs|
−τvln
(
1− leτv|vs|
)
τv >
le
|vs|
(2.43)
where τv is the momentum relaxation time-scale.
2.2.3.6 Secondary breakup
Liquid droplets may break up under the action of non-uniform surface forces that
are induced by their motion relative to the continuous phase. This phenomenon is
known as secondary breakup. The response of droplets to non-uniform surface
forces is invariably to deform, with the deformation resisted by the surface tension
and viscous forces inside the droplet. This behaviour can be measured with the
dimensionless Weber number (We) given by Equation 2.44.
We = ρg |vrel|
2
Dp
σ
(2.44)
STAR-CCM+ provides different physics models for the numerical study of the
breakup of liquid droplets in a gaseous stream. In the present numerical study,
the secondary breakup has been modelled through the Taylor Analogy Breakup
(TAB) model. This model uses the Taylor analogy described by O’Rourke et
al. [116], which represents a distorting droplet as a damped spring-mass system.
It considers only the fundamental mode of oscillation of the droplet whereas the
displacement and velocity of the mass in the spring-mass system correspond to
representative distortion and rate of distortion quantities for the droplet. De-
spite being based on a single mode of oscillation in the vibrational regime, the
TAB model reproduces the same characteristic time-scales in low and high Weber
number limits (We<100).
66
2.2. Numerical Model
Droplet Distortion
The goal of the TAB distortion model is to calculate the instantaneous displace-
ment x of the droplet equator from its equilibrium position. This displacement is
illustrated in Figure 2.16. For simplicity of analysis, this displacement is normal-
ized to the droplet diameter, as shown in Equation 2.45.
Figure 2.16: Illustration of the droplet distortion.
y = 2x
Cb ·Dp (2.45)
where Cb is an empirical constant (Cb=0.5), x is the instantaneous displacement
of the droplet from its equilibrium position and Dp is the droplet diameter. The
Taylor analogy between a distorting droplet and a damped spring-mass system
gives a second-order ordinary differential equation, as expressed by Equation 2.46.
ρlD
2
py
4 =
Ckσ
Dp
(
We
Wecrit
− 2y
)
− Cdµly˙ (2.46)
where σ and µl are the surface tension and viscosity of the droplet, respectively.
Cd, Ck and Wecrit are empirical constants with the following values:
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Cd = 5; Ck = 8; Wecrit = 12;
Droplet Breakup
The TAB breakup model relies on the TAB distortion model to calculate the
normalized droplet distortion (See Equation 2.45). When the droplet oscillations
reach a critical value (y=1), the droplet is assumed to be critically distorted and
a breakup event is then triggered. The Sauter mean diameter D32 of the post-
breakup droplets is related to the diameter Dp of the parent droplet through an
energy balance, giving:
Dp
D32
= 1 + KC
2
bCk
5 +
3C2bmp
4σpi
(
K
5 −
C2v
6
)
y˙2 (2.47)
where Ck and Cb are inherited from the TAB distortion model, K is the ratio
of the total energy in distortion and oscillation to the energy in the fundamental
mode. In STAR-CCM+, the breakup replaces the parent droplets with child
droplets whose diameter is chosen from a Rosin-Rammler distribution with the
Sauter mean diameter given by Equation 2.48. Post-breakup parcels are also
given a velocity normal to the original velocity of the parent parcel (See Equation
2.48). This is proportional to their rate of distortion at the instant of breakup y˙b.
v⊥ =
1
2CvCbDpy˙
2
b (2.48)
where Cv is the normal velocity coefficient (Cv=1).
Due to the high velocity gradients in the outlet of the IC-1.1, the primary
atomization was assumed to occur before the droplet injectors, which were placed
2 mm away from the catheter tip as an estimation of the distance between the the
APS nozzle and the laser beams that measures the droplets properties. It must
be noted that the APS has the potential to measure the properties of droplets
between 0.5 µm - 20 µm, associated with the secondary breakup, and not the
fragmentation and formation of ligaments related to the primary breakup.
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2.2.3.7 Interaction between continuous phase and dispersed phase
The interactions between the continuous phase and the dispersed phase can be
modeled as one-way coupling or two-way coupling. The coupling refers to the way
that momentum, heat and mass are exchanged between the phases.
With one-way coupling, the continuous phase influences the dispersed phase,
but not in the reverse direction. With two-way coupling, the effects of the dispersed
phase on the continuous phase such as displacement, interphase momentum, mass,
and heat transfer are taken into account (See Figure 2.17). The displacement of
the continuous phase by the dispersed phase is accounted for through the volume
fraction. The volume fraction of a Lagrangian phase is the fraction of the local
cell volume which that phase occupies.
Figure 2.17: (a) One-way coupling and (b) Two-way coupling interaction.
The volume fraction φc of a Lagrangian phase is seen as a void by the continuous
phase. The volume available for the continuous phase decreases by this fraction
and, in practice, φc is under-relaxed to promote stability:
φc = α
(∑
φ
)
+ (1− α) · φc,old (2.49)
where α is an under-relaxation factor of the two-way coupling solver and
∑
φ
is the sum of the volume fractions of the relevant Lagrangian phases. The value of
φc which is contributed to the continuous phase void fraction is limited to min(φc,
φc,max) again to promote stability.
The Lagrangian dispersed phase equations, when integrated over a cell, yield
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the changes in the momentum, mass and energy of each droplet between its entry
and exit. The sum of these changes for all droplets crossing the volume provides
the net momentum, mass and energy that is exchanged with the continuous phase.
These net exchanges enter the continuous phase equations as source terms.
2.2.4 Numerical Procedure
The CFD code used in the present thesis, STAR-CCM+, provides multiple flow
solvers that address different categories of fluid flow. These solvers include the
viscous flow solver, the segregated flow solver and the coupled flow solver. Choosing
the correct solver is one of the first steps in a flow analysis. According to the
guidelines of the CFD code, for an external flow of a Newtonian fluid, theCoupled
Flow model is the solver suggested to provide more robust and accurate solutions
in compressible flows with Mach numbers in the range expected in this application
(0.7 < Ma < 1.2). The scheme of Figure 2.18 represents the procedure followed
for the resolution with the coupled flow model.
Figure 2.18: Numerical procedure followed for the resolution with the Coupled
Flow model.
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With the coupled solver, the conservation equations for continuity, momentum
and energy are solved in a coupled manner, that is, they are solved simultaneously
as a vector of equations. The velocity field is obtained from the momentum equa-
tions, the pressure is calculated from the continuity equation and the density is
evaluated from the equation of state.
Figure 2.19 summarizes the steps carried out to run the numerical simulations.
Initially, the continuity and Navier-Stokes equations were solved for the continuous
phase (airflow) in steady state. Once the steady state air solution was converged,
the numerical results were saved and used as the initial condition to run the
unsteady state simulation with both phases, the continuous phase (airflow) and
the discrete phase (PFC droplets).
Figure 2.19: Steps carried out to run the numerical simulations.
This system of equations is solved by either the explicit or the implicit time-
integration scheme. In the present thesis the implicit scheme with a first order
temporal discretization has been chosen with a Courant number (CFL) value
of 50 in order to facilitate the convergence of the solution. The CFL condition,
defined by Equation 2.50, expresses that the distance that any information travels
during the time-step length must be lower than the distance between mesh ele-
ments, i.e., the information from a given mesh element must propagate only to its
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immediate neighbours.
CFL = u∆t∆x (2.50)
where u is the velocity magnitude, ∆t is the time-step and ∆x is the length
interval.
A time-step in an unsteady simulation advances the solution from time t to
time t+ ∆t. A single iteration of the unsteady solver for the LMP model involves:
1. Recovering the Lagrangian Multiphase solution at time t.
2. Advancing the Lagrangian Multiphase solution to time t + ∆t by time-
marching. A local time-step is used for each parcel. The time-step is adjusted
dynamically according to the time-step controls in force.
These two steps are executed in each iteration of the unsteady solver, before the
flow solver. Additionally, with the two-way coupling model active, the source terms
that the Lagrangian phase models compute are stored for subsequent application
in their respective transport equations. The Hybrid Gauss-Least Squares Method
has been used for the evaluation of the variable gradients and the Cell Cluster
property of the Source Smoothing method has been activated to control the size to
the large-scale cells. This option uses a cell clustering technique to group together
cells to form a coarser mesh on which to pass data. The size of the cluster is then
independent of the underlying mesh size, ensuring that droplets are always smaller
than the mesh used for coupling with the flow.
For parallel processing, the traditional approach to decompose the volume
mesh is to provide each processor with approximately the same number of cells.
For cases where the same Eulerian flow equations are solved in each cell, this ap-
proach generally gives good performance. However, for cases containing particles
(droplets in this study), this traditional form of decomposition can lead to imbal-
anced CPU loads across the parallel cores. If one or two partitions contain most of
the droplets, they will require significantly more computation time than partitions
with few droplets. The traditional decomposition method does not account for
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this difference. STAR-CCM+ provides an alternative approach which takes into
account the presence of droplets in the domain decomposition. The Lagrangian
load-balancing solver collects information about the computational load that
is required to solve droplet physics in each Eulerian cell and passes it to the par-
titioning solver, which coordinates the final load balancing (see scheme of Figure
2.20). This approach optimizes the domain decomposition in response to chang-
ing droplet distributions and the computational load across all CPU cores remains
balanced as droplets migrate throughout the domain.
Figure 2.20: Scheme of domain decomposition approaches.
2.2.5 Temporal and Discrete Phase Discretization
The determination of the temporal discretization for a simulation is based on the
adequate resolution of an unsteady physical phenomenon. In this case, due to the
unsteady characteristics of the aerosols produced with the IC-1.1, it was necessary
to define the temporal discretization in the numerical model, which consists of
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solving the unknowns of the flow in a specific instant. To that end, it is neces-
sary to indicate how often is desired to obtain these unknowns by means of the
time-step (∆t). The larger the ∆t value, the larger the temporal discretiza-
tion error, since the solver is not able to capture the whole unsteady physics of
the problem. However, the computational cost increases exponentially as the ∆t
value is decreased. Therefore, in order to obtain a time-step independent solution,
different ∆t values were studied and finally a constant ∆t of 1·10−4 s has been
chosen taking into consideration the relation between the accuracy of the results
and the computational cost. Additionally, 300 inner iterations per time-step has
been defined to achieve the convergence of the numerical solution.
From the computational standpoint, solving the trajectories of hundreds of
thousands of physical droplets that form part of the aerosol is extremely expen-
sive. For this reason, the CFD code uses the concept of parcel to reduce the
computational cost. Each parcel represents a group of droplets that have the
same physical properties (temperature, velocity, mass fraction, etc). Therefore,
the total population of droplets is represented by a small number of computa-
tional parcels instead. Similar to the number of cells, the number of parcels is not
arbitrary; it must be large enough to represent accurately the full population of
the aerosol droplets. In that sense, a parcel dependency study has been carried
out to control the discretization accuracy of the droplet population. This is visible
from a monitor plot of the droplet mass flow at the outlet of the computational
domain. The results for the PFD compound at 4 bar were monitored with three
different number of parcels injected per time-step (100 parcels/∆t, 500 parcels/∆t
and 1000 parcels/∆t), as illustrated in Figure 2.21. An increase in the number of
parcels injected improves the accuracy of the solution. It was necessary to take
a balance between the computational time, the convergence and the accuracy of
the solution to choose the optimal number of parcels. A considerable difference
was observed between the case with 100 and 500 parcels/∆t. After analyzing the
results, and due to the high difference in computational time between the cases of
500 and 1000 parcels/∆t it was concluded that the resolution with 500 parcels/∆t
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provides the best relation between accuracy and computational cost to discretize
the droplet population of the aerosol.
Figure 2.21: Discrete phase dependency study.
2.2.6 Continuous and Discrete Phase Simulation Results
Firstly, Navier-Stokes and continuity equations were solved for the continuous
phase in steady state. The results of the converged solution were saved and sub-
sequently used as the initial condition for the transient simulation of both phases,
i.e., the airflow and the parcels representing the discrete phase. The solution of
the continuous phase is illustrated in Figures 2.22 - 2.23 with the airflow velocity
fields. As expected, the largest axial velocity values were observed close to the
catheter tip with 391 m/s and 455 m/s for pressures of 4 and 5 bar, respectively.
The velocity in the injectors’ position was 247 m/s and 293 m/s for 4 and 5 bar
of driving pressure, respectively. These values were checked in order to define the
initial velocity condition of the PFC droplets in the injector points. The high
air velocity values obtained confirms the importance of considering the airflow as
compressible flow in this application.
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Figure 2.22: Continuous-phase velocity magnitude with a pressure of P=4bar.
Figure 2.23: Continuous-phase velocity magnitude with a pressure of P=5bar.
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The solution of the discrete phase is illustrated in Figure 2.24 with the forma-
tion of the aerosol cone with FC75 at 4 bar. The solution was taken 0.06 s after the
release of droplets from the injectors. The transitory condition of the aerosol flow
changes the distribution of droplets with time. For that reason, it was necessary
to track a representative sample of 0.01 s in order to study the numerical results.
Figure 2.24: Particle size distribution of the FC75 discrete droplets with a driving
pressure of 4 bar.
2.2.7 Convergence Criteria
When running a numerical simulation it is important to establish a convergence
criterion to define when the calculation has reached the final solution. The con-
vergence of a numerical process can be stated as the solution of the system of
algebraic equations approaching the true solution of the partial differential equa-
tions having the same initial and boundary conditions as the refined grid system
[117]. This system of algebraic equations is usually solved iteratively by the CFD
codes. During the numerical procedure, the imbalances (errors) of the discretized
equations are monitored and they are referred as the residuals of the system of
algebraic equations. For a satisfactory convergence, the residuals should diminish
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as the numerical process progresses. In the current thesis, the solution was con-
sidered converged with a three-order-of-magnitude drop in the numerical residuals
[118]. Additionally to the residuals it is advisable to monitor a quantity of inter-
est to ensure the stability of the solution. In this case, the evolution of the axial
velocity in a point at the outlet of the computational domain has been monitored,
see Figure 2.25. The criterion used to consider that the axial air velocity at the
outlet is stable has been to verify that the velocity varies less than 0.1% every
1000 iterations. Figure 2.26 shows the evolution of the axial velocity throughout
the numerical process with a variation of 0.0087% in the last 1000 iterations.
Figure 2.25: Coordinates of the point chosen to monitor the evolution of the axial
air velocity.
Figure 2.26: Axial air velocity values with pressures of 4 bar and 5 bar, considered
to confirm the convergence of the numerical solution.
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2.2.8 Validation of the Numerical Model
The axial velocity results with a pressure of 4 bar were monitored at several dis-
tances from the catheter tip and validated with the experimental results obtained
by Goikoetxea et al. [98]. The turbulence model chosen along with the mesh
refinement generated close to the catheter tip led to an accurate prediction of the
airflow velocity values, as shown in Figure 2.27 [119].
Figure 2.27: Experimental and numerical axial air velocity profiles at different
distances from the IC-1.1 tip.
The results of the cumulative mass distribution as a function of the droplet
size (Ydg) are presented in Figures 2.28 and 2.29 for PFD and FC75 compounds,
respectively, and were compared with the experimental data obtained by means of
the APS. Some differences were found between the numerical and the experimental
results. The collision and coalescence of the droplets may be the cause of those
deviations. In the numerical model, which considered the breakup of the droplets
with the TAB breakup model but not the coalescence, a higher cumulative mass
fraction was obtained for droplets above 3 µm for the PFD compound at both
pressures and for each distance studied. For the FC75 compound, with a pressure
of 4 bar, the cumulative mass fraction was higher for droplets below 5 µm and
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considerable lower for droplets above 10 µm. With a pressure of 5 bar there was a
different pattern in the experimental results and the cumulative mass fraction for
droplets above 10 µm was considerable higher.
Figure 2.28: Experimental and numerical cumulative mass distribution based on
droplet size for the PFD compound.
Figure 2.29: Experimental and numerical cumulative mass distribution based on
droplet size for the FC75 compound.
2.2.9 Conclusions
This chapter has studied the generation of a PFC aerosol by means of an inhalation
catheter, the IC-1.1, and its main parameters measured experimentally with an
APS and numerically with CFD techniques [120]. Different cases were studied
for PFD and FC75 varying the driving pressure of the compressed air between
4 and 5 bar. The results were measured at the optimal distances between the
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APS nozzle and the catheter tip and at some additional distances in the case
of PFD. The GSD values varied from 1.61 to 2.04, leading to the formation of
heterodisperse aerosols. The aerodynamic diameter (Da) provided values that
were within the recommended range values (1-5 µm) and, although the MMAD
results were between 5-10 µm, we must take into account that the goal of this
study is the generation of an aerosol beyond the nasopharyngeal region, avoiding
in that way the deposition of these bigger droplets.
Subsequently, the numerical model was introduced in order to simulate the
generation of the PFD and FC75 aerosols with CFD tools. These numerical simu-
lations were validated with the axial velocity results obtained experimentally with
a hot-wire anemometer [98], confirming their accuracy at different downstream po-
sitions. The differences in the cumulative mass distribution of the aerosol droplets
between the numerical and experimental procedure suggest that the collision and
coalescence of the PFC droplets may play an important role during the formation
of the aerosol. Similar behavior could be seen for PFD at both driving pressures
studied, whereas for FC75, the cumulative mass fraction for droplets above 10 µm
was considerable higher with a driving pressure of 5 bar. The numerical study
presented in this thesis could be a helpful tool to carry out parametric studies
with new prototype nebulizers to treat the RDS in preterm babies.
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CHAPTER 3
NEBULIZER PROTOTYPE
DESIGN
3.1 Additive Manufacturing Techniques in
Medical Applications
Additive manufacturing consists in the manufacturing process of a three-dimensional
object created by superimposing successive layers of material. This development
allows the creation of complex 3D prototypes, curved surfaces, cantilevers and
interior ducts that could hardly be manufactured using conventional technology.
Lee et al. [121] summarized the fundamental aspects of additive manufacturing
processes in terms of resolution, speed and specific energy as well as the introduc-
tion of new novel advanced materials with specific properties. Ligon et al. [122]
reviewed the development of polymers and advanced polymer systems specifically
for additive manufacturing.
The manufacture of 3D models requires a pre-printing process which consists
in the configuration and programming of the model to be printed in the specific
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software of each machine. This process is summarized with the following steps:
(See Figure 3.1).
1. Design the 3D model by means of CAD software.
2. Export the 3D model to printable .STL format (triangular mesh).
3. Import the 3D model into the machine-specific printing software.
(a) Model slicing (Layers generation).
(b) Model orientation (Avoid or reduce the printing of supports).
(c) Supports generation.
(d) Material configuration (Temperature of manufacturing, print speed...).
4. Launch the processed model to 3D printer to start the manufacturing.
Figure 3.1: Steps involved in the configuration and programming of the pre-
printing process. Source: provided by Optimus 3D company.
Over the last years, the use of additive manufacturing techniques has experi-
enced an upsurge for the development of new biomedical devices due to its
flexibility and versatility to reproduce complex geometries and personalized prod-
ucts. Vukicevic et al. [123] analyzed the application of 3D printing techniques to
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create models of congenital heart defects for anatomic teaching or medical train-
ing. Regarding the study of respiratory issues, Cheng et al. [124] manufactured
a customized nasal mask cushion for a CPAP device to fit a particular patient’s
face. Two rapid prototyping techniques were compared and it was found that the
customized cushion provided a better fit between the face and the cushion and
less leakage compared with two other similar commercial cushions. Vermeulen
et al. [125] presented a case study where a patient-specific airway geometry was
used to manufacture a 3D model and to perform a flow analysis by a particle im-
age velocimetry system. Recently, Copploe et al. [126] have developed a neonate
eight-generation airway model by means of additive manufacturing techniques to
study the distribution of instilled surfactant, see Figure 3.2. This work showed
the potential of 3D printed models to carry out quantitative studies of surfactant
delivery into the respiratory system and to identify the best conditions that lead
to an optimal distribution.
Figure 3.2: Eight-generation neonate airway model created with additive manu-
facturing techniques by Copploe et al.[126].
3.1.1 Additive Manufacturing Technologies
Additive manufacturing covers various technologies with the same principle of
superposition/addition of material but with technical differences for each case and
application. The following list summarizes the most common technologies; the rest
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will comprise the same manufacturing base having different specific characteristics
(manufacturing speeds, materials, software, hardware ...).
• Fused Deposition Modeling (FDM): The filamented polymer melts and
the head extrudes the material by depositing it layer by layer on the printing
plate. The superposition of the layers will create the 3D model. One of
the most common materials used with this technology is the acrylonitrile
butadiene styrene (ABS), a thermoplastic polymer mainly known for its good
resistance to low temperatures and its light weight. The layer resolution,
depending of the machine, oscillates between 0.127-0.330 mm.
• Selective Laser Melting (SLM): It is a technology specially developed
for 3D printing of metal alloys. It generates additive parts by melting the
metal dust particles layer by layer in an integral fusion process creating a
homogeneous block with high resistance. The materials used are usually
nickel-based, titanium, stainless steel and aluminium alloys with a layer res-
olution approximately of 0.05 mm.
• Selective Laser Sintering (SLS): It was developed and patented in the
mid-1980s by Deckard and Beaman [127]. This technique uses a laser as
the power source to sinter powdered plastic material into a solid structure
based on a 3D model. It uses a comparable concept to SLM, but sintering
the material instead of melting. The most common materials used with this
technology includes polymers such as polyamides and polystyrenes. The
layer resolution oscillates between 0.060-0.150 mm, depending on the 3D
printer used.
• Multi Jet Fusion (MJF):With the Multi Jet Fusion technology, developed
by the commercial brand HP, a thin layer of powder is spread over the build
platform where it is heated to a near-sintering temperature. MJF provides
faster cooling times and greater recyclability than SLS with recovered powder
values up to 80-85%. The main material used is PA 12 (nylon) with an
approximate layer resolution of 0.08 mm.
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• Stereolithography (SLA): This additive manufacturing process uses a liq-
uid resin that becomes solid when exposed to the light from an ultraviolet
laser. The liquid resin is solidified through a process called photopolymer-
ization, where the monomer carbon chains that compose the liquid resin are
activated by the ultraviolet laser light, creating strong unbreakable bonds be-
tween each other. It provides good resolutions at 0.05-0.127 mm, depending
on the 3D printer used.
• PolyJet: This technology is an improvement over the SLA technique. Both
of them use ultraviolet energy to cure plastics but their differing build styles
separate them in terms of accuracy and applications. This technology is
based on the photopolymerization of resin, which consists in the projection
of micro droplets over a platform along with an emission of ultraviolet light
that solidifies the material with a curing procedure. This process is repeated
creating the desired geometry, layer by layer, until obtaining the model part,
which will not need any subsequent stage, and getting the manufacturing of
great precision parts with complex geometries. PolyJet uses multiple print
heads to deposit liquid plastic onto a clean build platform layer by layer.
The speed and fine resolution of PolyJet make this technology ideal for the
manufacturing of highly detailed prototypes, with a layer resolution up to
16 µm.
3.2 Application of 3D Printing Techniques to
Manufacture a Nebulizer Prototype
Further research is needed to develop a suitable device for neonates in order to
optimize the drug delivery in a non-invasive and effective way. To that end, ad-
ditive manufacturing techniques have been chosen for the development of a new
nebulizer prototipe due to the versatility and flexibility of this technology. How-
ever, the small dimensions required to obtain an accurate nebulization made this a
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challenging manufacturing process. Two different prototypes have been developed,
allowing the aerosol generation and offering potential to drug delivery without the
need of intubation. Both protoypes designed are classified within twin-fluid neb-
ulizers with external mixing, i.e., the gas interacts with the liquid outside of the
nebulizer. Twin-fluid nebulizers typically produce a full cylindrical spray cone
with relatively small droplets at high liquid mass flow rates [128]. Prototype 1
consists of six small outer lumens, where compressed air is delivered, and a central
lumen where the liquid flows. On the other hand, in the Prototype 2, the outer
lumens have been replaced with two half-circular rings. The central lumen has the
same dimensions in both prototypes and the area of the two half-circular ring in
Prototype 2 is equal to the area of the six outer lumens of Prototype 1. Figure 3.3
shows the distal geometry of each prototype and their main dimensions. Drawings
with all the geometry details of both prototypes are added in Appendix A.
(a) (b)
Figure 3.3: (a) Distal geometry dimensions of Prototype 1 and (b) Prototype 2.
(Dimensions are given in mm).
3.2.1 Prototypes Manufacturing with PolyJet Technology
The manufacturing of all the prototypes presented in the current thesis have been
developed by the company OPTIMUS 3D, located in the Álava Technology Park.
Initially, it was considered to use the Polyjet technology by means of the Stratasys
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Objet30 Pro 3D printer, see Figure 3.4a. The resolution of this machine allowed
to print the prototypes proposed with all the necessary details.
(a)
Objet30 Pro
Maximum Build
Size (XYZ)
294 x 192 x 148.6 mm
Resolution 600 x 600 x 900 DPI
Layer Thickness 16 µm
Model Material VeroClear Transparent
Support
Material
SUP705 (WaterJet
removable)
(b)
Figure 3.4: (a) Stratasys Objet30 Pro 3D printer and (b) its specifications.
Initially, preliminary printing tests were performed with a section model of 82
mm in length, instead of the original total length dimension proposed of 131.9 mm,
in order to check the feasibility to print and clean a model of this length and such
small dimensions. This manufacturing system deposits material in the build tray
and, at the same time, it is solidified by means of ultraviolet light allowing to create
the model layer by layer. Support material is printed for the creation of models
with ring holes or that are cantilevered on the printing surface, which is finally
removed by means of pressurized water or by soaking the models in a solution of
caustic soda (sodium hydroxide). To facilitate the removal of this support material
and minimize the problems related with that, tolerance cylinders were designed as
shown in Figure 3.5. When the printing has ended, the model was introduced in a
solution of caustic soda to soften the support material and then the cylinders were
extracted, allowing to remove most of the support material. Finally, pressurized
water was used to remove the remaining support material.
The extraction of cylinder 1 (2 mm) could be carried out succesfully, as ob-
served in Figure 3.6b. However, the cylinders created for the outer and central
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lumen (0.75 mm) were not possible to be extracted and on several occasions the
cylinders broke during the process. It was also observed that the intersection be-
tween the two inlets was the more difficult part of the model to carry out the
removal of the support material.
Figure 3.5: Definition of the tolerance cylinders to facilitate the extraction of the
support material.
In conclusion, the Objet30 Pro 3D printer allowed to print the models and
the detail of the holes correctly but it was not able to remove the support
material by the use of pressurized water without causing the breakage of the
model. These initial tests showed that it was necessary to increase the diameter
proposed for the central and outer lumens in order to create stiff enough cylinders.
More preliminary tests were carried out, reaching to the conclusion that it was
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necessary a minimum lumen diameter of 2.5 mm to be able to remove cylinders
of 2 mm to clean correctly a model of the length proposed in Prototype 1 and
Prototype 2 (131.9 mm).
(a) Section of Prototype 1 printed
(82 mm in length).
(b) Extraction of tolerance cylinders to
remove the support material.
Figure 3.6: Preliminary tests carried out with the Objet30 Pro 3D printer.
These dimensions are far away of our requirements and, therefore, other differ-
ent additive manufacturing processes were taken into account to print the proto-
types proposed. Finally, the 3D Systems-ProJet MJP 5600 3D printer, illustrated
in Figure 3.7, was chosen for the development of the prototypes discussed in the
present thesis. This 3D printer, just as the Objet30 Pro used previously, is based
in the PolyJet technology and it has a height layer precision of 16 µm, allowing
the manufacturing of the holes required in the prototypes presented in this thesis.
It is a large format multi-material 3D printer that offers print speeds up to twice
as fast as similar PolyJet printers. In addition, thanks to the large volume of
printing, it has the advantage to reduce model costs up to 40% compared to 3D
printers for multiple competing materials.
The difference between both 3D printers consists in the application of the sup-
port material. The 3D Systems-ProJet MJP 5600, in comparison with the Objet30
Pro, offers the alternative of generating a specific wax support, which is re-
moved with heat after printing. This 3D printer uses flexible and rigid photopoly-
mers of the VisiJet family commercial brand. Specifically, the VisiJet CR-CL
(Clear Polycarbonate-like material) has been used in all the prototypes printed
and discussed in this thesis. Table 3.1 shows the specifications of this material.
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(a)
MJP 5600
Maximum Build
Size (XYZ)
518 x 381 x 300
mm
Resolution 600 x 600 x 1600
DPI
Layer Thickness 16 µm
Model Material VisiJet CR-CL
Support
Material
VisiJet S500
non-toxic wax
(b)
Figure 3.7: (a) Stratasys Objet30 Pro 3D printer and (b) its specifications.
Properties VisiJet CR-CL
Composition Ultraviolet curable plastic
Description Rigid polycarbonate-like
Color Translucent clear
Solid Density 1.18 g/cm3
Tensile Strength 37-47 MPa
Tensile Modulus 1000-1600 MPa
Elongation at Break 7-16 %
Flexural Strength 61-72 MPa
Flexural Modulus 1400-2000 MPa
Impact Strength (Notched Izod test) 16-19 J/m
Water Absorption 0.5 %
Shore A Hardness N/A
Shore D Hardness 76-80
Heat Distortion Temperature 46 ◦C
Table 3.1: Material properties.
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Figure 3.8: (a) General visualization of the nebulizer prototype design proposed,
distal section of (b) Prototype 1, (c) Prototype 2. Manufacturing result of Pro-
totype 1 (d), distal section detail of the manufactured (e) Prototype 1 and (f)
Prototype 2.
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3.3 Experimental Setup with the Prototypes
Both prototypes were tested with the same compounds that were used in the
experimental study carried out with the IC.1.1 described in the previous chapter;
distilled water (H2Od), PFD and FC75. Their properties are shown in Table
3.2. Figure 3.9 illustrates the experimental setup used to measure the droplet size
distribution of the aerosols generated with Prototype 1 and Prototype 2. The mass
median aerodynamic diameter (MMAD), the aerodynamic diameter (Da) and the
geometric standard deviation (GSD) were analyzed by means of the APS.
Parameter H2Od PFD FC75
Density (ρ) [g/ml] 0.99 1.95 1.78
Kinematic viscosity (υ) [cSt] 1.003 2.70 0.81
Surface tension (σ) [dyn/cm] 73 15 15
Table 3.2: Properties of H2Od and PFCs.
Figure 3.9: Experimental setup used for the particle size characterization with the
nebulizer prototypes.
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The same air pressure controller described in the experimental study with
the IC-1.1 (LABneb, Trudell Medical International), with an operating range of
0-7 bar, has been used. It provides compressed air to both the small piston placed
within the liquid chamber and to the side connection of the nebulizer prototypes,
where the air is delivered to the outer lumens and to the two half-circular rings
respectively. The air was supplied by an air cylinder shoulder (Alphagaz 1
Air) with purity higher than 99,999% assuring that the air delivered is empty of
impurities that could block the nebulizer prototypes lumens or the APS nozzle. A
pressure reducer was included to regulate the pressure from the 200 bar supplied
by the air cylinder shoulder to an interval of 0-10 bar, necessary to control the air
pressure provided to the air pressure controller, see Figure 3.10.
(a) (b)
Figure 3.10: (a) Air cylinder shoulder with the pressure reducer included and (b)
detail of the connections to the air pressure controller.
The distance between the inlet nozzle of the APS and the distal section of the
nebulizer prototypes was controlled during the experiments in order to get a value
as close as possible to the average droplet concentration of 1000 droplets/cm3. All
the samples collected with the APS were recorded, stored and analyzed by the
Aerosol Instrument Manager software associated with the instrument.
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Figure 3.11 shows in detail how the nebulizer prototype was connected. The
central inlet of the prototype, where the liquid is delivered, was first connected to
a three-way stopcock valve to control the charge of the compound into the liquid
chamber whereas the side connection was directly connected with the air pressure
controller.
(a) (b)
Figure 3.11: (a) Setup of the nebulizer with the liquid chamber where the liquid
is supplied and (b) detail of the connections to administer the compressed air and
the liquid respectively.
Statistics
A statistical analysis was carried out with the data obtained. The measure-
ments were repeated five times for each compound and prototype and the mean
± standard deviation were calculated for the Da, MMAD and GSD. A one-way
analysis of variance (ANOVA) was performed to identify any statistically signifi-
cant difference between the prototypes and each compound for aerosolization rates
with a p<0.05 accepted as significant.
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3.4 Experimental Results with Distilled Water
The distance between the APS inlet nozzle and the distal part of the prototypes
was controlled in order to obtain a droplet concentration value close to 1000
droplets/cm3, as recommended. This distance varied depending on the prototype,
compound used and the driving pressure applied. Thus, with the experiments
carried out with H2Od, this optimal distance was found at 19-24.2 cm and 24-28
cm with Prototype 1 and Prototype 2 respectively.
The aerosols produced by Prototype 1, during H2Od aerosolization, provided
MMAD values lower than 9 µm. Specifically, a minimum value was observed with
a driving pressure of 1 bar (5.96 ± 0.76 µm) and a maximum value with a driving
pressure of 2 bar (8.80 ± 1.84 µm), see Figure 3.12a. On the contrary, larger
MMAD measurements were achieved during aerosolization with Prototype 2 with
values up to 15 µm. A minimum value with a driving pressure of 1 bar (13.03
± 2.62 µm) and a maximum peak with a driving pressure of 2 bar (14.93 ± 1.13
µm) were obtained. It should be noted that for both prototypes the minimum and
maximum MMAD values were obtained for the same driving pressures, 1 and 2
bar respectively.
(a) (b)
Figure 3.12: (a) MMAD (µm) and (b) Da (µm) values for Prototype 1 and Pro-
totype 2 as a function of the driving pressure for distilled water (H2Od). Values
are given as mean ± standard deviation.
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With regard to the aerodynamic diameter (Da), the results obtained with Pro-
totype 1 and H2Od maintained a stable value regardless of the driving pressure,
between 3.32 ± 0.20 µm (1 bar) and 3.40 ± 0.31 µm (1.5 bar). Prototype 2,
however, presented a smooth increment in the Da proportionally with the driving
pressure, as shown in Figure 3.12b.
According to the GSD values obtained, both prototypes produced aerosols with
many different sizes (heterodisperse aerosols), as shown in Table 3.3, with GSD
values between 1.79 ± 0.03 (Prototype 1 at 1 bar) and 2.47 ± 0.28 (Prototype 2
at 2 bar).
GSD
P (bar) Prototype 1 Prototype 2
1 1.79 ± 0.03 1.95 ± 0.31
1.5 1.86 ± 0.05 2.31 ± 0.26
2 1.86 ± 0.06 2.47 ± 0.28
3 1.90 ± 0.05 2.37 ± 0.12
Table 3.3: Geometric standard deviation (GSD) for both prototypes nebulizing
H2Od at different pressures. Values are given as mean ± standard deviation.
Figure 3.13 represents the droplet mass and number distribution of one of
the aerosol samples taken for H2Od with each prototype and suplying the same
driving pressure of 1.5 bar. From there, it can be visualized how the droplet mass
concentration with Prototype 1 (see Figure 3.13a) is transported by droplets in a
wider range than Prototype 2, where most of the aerosol mass is formed by droplets
of 10-20 µm (see Figure 3.13b). However, taking into account the concentration
number, Prototype 2 presents most of the droplets classified below 3 µm (see Figure
3.13c-3.13d), which is in concordance with the difference between the values of Da
and MMAD explained. The different behavior of Prototype 2 with respect to
Prototype 1 may be attributed to the half-circular ring geometry proposed for the
air delivery and its possible influence in the breakup and coalescence of the aerosol
droplets.
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Prototype 1 (P=1.5bar) Prototype 2 (P=1.5bar)
(a) Mass % concentration (b) Mass % concentration
(c) Number % concentration (d) Number % concentration
Figure 3.13: Mass and number distribution of an H2Od aerosol sample with Proto-
type 1 (left) and Prototype 2 (right). (Screenshots taken directly from the Aerosol
Instrument Manager software).
3.5 Experimental Results with PFCs: PFD and
FC75
After these initial tests carried out with H2Od, PFCs were tested in order to study
in detail the behaviour of both nebulizer prototypes under a compound that can
be used subsequently as a mixture with surfactant. Similarly, the optimal distance
between the APS inlet nozzle and the distal part of the prototypes was controlled
to take the measurements. With PFD this distance varied between 9-22.5 cm and
with FC75 between 7-19 cm, depending on the prototype used and the driving
pressure applied.
With regard to the MMAD values, the results with both prototypes showed
relatively uniform values, close to 12 µm, for the two driving pressures considered.
The largest value (13.08 ± 0.36 µm) was obtained with PFD and Prototype 1
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applying a driving pressure of 3 bar, whereas Prototype 2 with FC75 provided a
minimum value of 11.96 ± 0.17 µm (see Figure 3.14a). The large difference in the
MMAD results obtained, compared with those under H2Od, may be caused due
to the high volatility of the PFCs compounds.
The Da in all cases tested was below 5 µm, as shown in Figure 3.14b. The
results with Prototype 2 were slightly lower than those obtained with Prototype
1 for each case and driving pressure. In addition, larger values were achieved with
PFD irrespective of the prototype geometry and the pressure defined. The two
half-circular rings surrounding the Prototype 2, where the air is delivered, instead
of the circular lumens of Prototype 1, may contribute to a larger breakup of the
PFCs and, therefore, the generation of smaller droplets. The largest Da value was
achieved with Prototype 1 and PFD (5.00 ± 1.38 µm) whereas Prototype 2 with
FC75 provided the minimum value (2.87 ± 0.07 µm). In addition, for the same
pressure and the same prototype, the size of the droplets was smaller for the case
with FC75 in comparison with PFD, as shown in Figure 3.14b. The reason could
be found in the fact that the vapor pressure of the FC75 (63 mmHg) is four times
larger than the PFD (14 mmHg). In the case of FC75, the nebulization might lead
to the development of smaller droplets or even the generation of PFC vapor [71]
[103].
(a) (b)
Figure 3.14: (a) MMAD (µm) and (b) Da (µm) values for Prototype 1 and Proto-
type 2 as a function of the driving pressure for PFD and FC75. Values are given
as mean ± standard deviation.
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As happened with H2Od, both prototypes produced heterodisperse PFC aerosols
with GSD values between 2.00 ± 0.08 (Prototype 2 with FC75 at 1.5 bar) and 2.34
± 0.02 (Prototype 2 with PFD at 1.5 bar), as detailed in Table 3.4.
GSD
Prototype 1 Prototype 2
P (bar) PFD FC75 PFD FC75
1.5 2.23 ± 0.14 2.26 ± 0.12 2.34 ± 0.02 2.00 ± 0.08
3 2.24 ± 0.10 2.25 ± 0.08 2.29 ± 0.02 2.04 ± 0.02
Table 3.4: Geometric standard deviation (GSD) for both prototypes nebulizing
PFD and FC75 at different pressures. Values are given as mean ± standard devi-
ation.
Figure 3.15 and 3.16 represents the droplet mass and number distribution ob-
tained by means of the APS of one of the aerosol samples taken for PFD and
FC75, respectively. In the post-process it must be noted that for PFD and FC75
compounds, whose density is out of the 0.9-1.1 g/cm3 range, it is necessary to
apply the Stokes correction to obtain the corrected aerodynamic diameter (Da2);
see Equations 3.1-3.3. For the correction of the diameter Da1 measured with the
APS several parameters are taken into account: the dynamic viscosity and the air
density at 20◦C (µair, ρair), the air velocity through the nozzle (U=15000 cm/s),
the average droplet velocity (V¯ ), the PFC compound density used (ρ) and the
density of the polystyrene latex particles used by the manufacturer to calibrate
the system (ρPSL=1.05g/cm3).
Da2 = Da1
[
6 +R2/32
6 +R2/31
]1/2
(3.1)
R1 =
ρair
(
U − V¯ )Da1
µair
√
ρPSL
(3.2)
R2 =
ρair
(
U − V¯ )Da2
µair
√
ρ
(3.3)
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Prototype 1 (P=1.5bar) Prototype 2 (P=1.5bar)
(a) Mass % concentration (b) Mass % concentration
(c) Number % concentration (d) Number % concentration
Figure 3.15: Mass and number distribution of a PFD aerosol sample with Proto-
type 1 (left) and Prototype 2 (right).
Prototype 1 (P=1.5bar) Prototype 2 (P=1.5bar)
(a) Mass % concentration (b) Mass % concentration
(c) Number % concentration (d) Number % concentration
Figure 3.16: Mass and number distribution of a FC75 aerosol sample with Proto-
type 1 (left) and Prototype 2 (right).
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3.6 Discussion and Conclusions
The current experimental study has been carried out to evaluate and compare
two novel nebulizer prototypes to generate respirable droplets with potential to
be delivered in the supraglottic region [129]. The prototypes were created by
additive manufacturing techniques and subsequently tested with an APS in order
to measure the particle size distribution. This study reflects the importance of the
nebulizers’ geometry and how it can affect in the aerosol size distribution. Figure
3.17 illustrates the nebulization process with each one of the prototypes proposed.
(a) (b)
Figure 3.17: (a) Nebulization case with Prototype 1 and (b) with Prototype 2.
A main finding of the evaluation of these two novel nebulizer prototypes was
that they produced droplets with aerodynamic diameters within the optimal range
recommended of Da=1-5 µm for its correct inhalation [130]. In the upper respi-
ratory tract, droplets of 2-5 µm are desirable. Droplets of size larger than 5 µm
are mainly deposited by impaction in the oropharyngeal region and are unable to
reach to the lungs, whereas droplets of size smaller than 1 µm are mostly exhaled
103
Chapter 3. NEBULIZER PROTOTYPE DESIGN
without deposition. It is also important to note that the MMAD values obtained
were between 6-13 µm and, therefore, a high amount of the aerosol is transported
by droplets larger than 5 µm. Nevertheless, a larger MMAD values might not be
a problem taking into account that the aim of these prototypes is to be placed
in the supraglottic region. Due to the spreading properties of viscous substances
as the surfactant, droplets with larger diameters than 5 µm could reach the lungs
along with finer droplets that could penetrate further into the smaller airways for
deep lung delivery [78].
With regard to Prototype 1, our findings with H2Od have shown similar values
in terms of Da compared with those obtained by Goikoetxea et al. [98] using
the Aeroprobe pneumatic catheter. In addition, PFCs provided slightly larger
Da values with both prototypes. In this study, the Da value varies in a range
of 3-5 µm while in Goikoetxea et al. [98] values approximately of 2 µm were
measured. This increment could be benefit to obtain a better deep lung deposition.
The difference in MMAD with PFCs between both studies is more pronounced,
since the prototypes proposed in the current thesis provided most of the aerosol
mass distributed in droplets within 10-20 µm. The results with the Aeroprobe
pneumatic catheter showed lower MMAD values even though the experiments
were also carried out at higher driving pressures (4-7 bar). On the other hand,
an important difference in the droplet size distribution was observed with the
atomizing system of Milesi et al. [79], where droplets with median diameter of
40-60 µm were measured at the tip of their catheter.
The study presents some limitations that must be acknowledged. During the
droplet size distribution measurements it was observed that the aerosolization rate
was too high to nebulize the 5 ml of compound contained in the liquid chamber
in each sample. This issue is directly related with the dimensions of the nebulizer
lumens of the prototypes manufactured, which were adjusted as close as possible
to the limitations of the additive manufcaturing technology and the 3D printer
used. The goal at this point is to adjust the dimensions of the lumens in the distal
tip of the prototypes in order to produce an aerosol with lower aerosolization rates,
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i.e., an increase in the aerosolization time to administer a dose. This will also lead
to a reduction in the distal pressure, which is indispensable not to exceed a value
of 10 cmH2O suggested by neonatologists. All these aspects are addressed in the
next chapter of this thesis for the design and manufacturing of new improved and
optimized prototypes.
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CHAPTER 5
CONCLUSIONS AND
FUTURE WORK
5.1 Conclusions
The present Chapter summarizes the main conclusions obtained from the analysis
of the experimental and numerical results obtained in this thesis, first with the
IC-1.1 and finally with the nebulizer prototypes designed and manufactured with
additive manufacturing techniques.
The experimental results obtained with the IC-1.1 provided aerosol
droplets with D¯a values within the recommended size values of 1-5 µm to be
considered respirables in the supraglottic region. Specifically, for both PFC com-
pounds studied at driving pressures of 4 and 5 bar, the results varied between 2.28
± 0.22 µm and 4.33 ± 0.01 µm. With regard to the MMAD, results between 5-10
µm were obtained with a minimum value of 4.83 ± 0.08 µm and a maximum value
of 10.01 ± 0.01 µm. These MMAD results indicate that the aerosol generated by
the IC-1.1 contains droplets larger than 5 µm. However, it must be taken into
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account that the aerosol is generated in the supraglottic region and, therefore, the
deposition of droplets larger than 5 µm in the nasopharyngeal region is avoided.
The GSD results varied from 1.61 ± 0.01 to 2.04 ± 0.02, leading to the formation
of heterodisperse aerosols.
The CFD numerical model developed is able to predict the downstream
behavior of the aerosol, i.e., the air flow and the droplets formed. The axial
velocity results with a pressure of 4 bar were monitored at several distances from
the catheter tip and validated with experimental data [98]. These models are
able to predict the cumulative mass distribution based on the aerosol droplets size
at the exit of the IC-1.1. The overprediction of the CFD numerical model with
respect to the experimental data suggests that the collision and coalescence of PFC
droplets, that was not included in the CFD model, may be a key factor during
the aerosol formation. In conclusion, the application of CFD techniques has been
proven as an interesting tool to study the droplet size and mass distribution of
the aerosol generated and, therefore, to research new nebulizer devices. It is also
important to specify that these type of CFD simulations are quite demanding in
time and require the use of High Performance Computing (HPC).
Additive manufacturing techniques have shown potential to create a new
nebulizer prototype able to generate respirable droplets to be delivered in the
supraglottic region. Specifically, the PolyJet technology has been considered the
best option to manufacture a prototype device with the dimensions and the accu-
racy needed for this type of application. The experiments carried out with both
prototypes showed D¯a values within the optimal range recommended of 1-5 µm
for its correct inhalation and MMAD values between 6-13 µm. It must be noted
that, even though the aerosol produced with these prototypes contains droplets
larger than 5 µm, the final goal of these nebulizer prototypes is to be used with
surfactant. The viscous properties of this compound facilitate its distribution be-
yond the trachea once deposited in the walls and, according to medical experts,
if surfactant reaches the third generation it would be sucessfully spread to the
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distal part of the lungs. Therefore, the experimental results obtained with the
nebulizer prototypes designed and manufactured in the current thesis offer an en-
couraging starting point to continue with their optimization and to carry out in
vivo experiments on animals.
5.2 Future Work
The following future lines of research are proposed to continue progressing in the
investigation of the RDS treatment with an aerosolized administration by means
of the nebulizer prototype devices presented in the current thesis.
5.2.1 CFD Studies with the Nebulizer Prototypes
For future investigations, it would be highly interesting to improve the CFD numer-
ical model presented in this thesis with the addition of new mathematical models.
In particular, it is recommended to study the implementation of the primary
atomization to achieve a connection between the nebulizer prototype geometry
and the formation of aerosol droplets. Nowadays, the CFD codes are working to
implement models, as the Linearized Instability Sheet Atomization (LISA) model,
to simulate the breakup of a thin liquid sheet. However, this model is proposed to
be implemented with special pressure-swirl atomizers that are used for combus-
tion processes and the simulations require of very long computational times and
the use of parallel computing with workstations. It is also suggested to include
in the CFD model the airways geometry where the nebulizer prototype will be
placed. In this case, it would be advisable to take into account the temperature
and relative humidity that exist within the airways. These factors may play an
important role in the droplet size distribution, with an approximate temperature
of 37◦C and a relative humidity close to a 100% in the respiratory system. Ad-
ditionally, it might be interesting to study the liquid fluid film to analyze the
behavior of the aerosol droplets deposited on the walls of the airways and to see
if they spread towards the lungs.
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5.2.2 Pressure Control System
The experiments performed with Prototype 4.2 (see Chapter 4) showed the poten-
tial to achieve an emptying rate of the compound contained in the liquid chamber
with the application of pressures in small ranges of 0.1-0.5 bar. However, the air
pressure controller used in these experiments, that has an operating range of 0-7
bar, does not allow to control accurately the pressure in these small intervals. For
that reason, it has been considered to include a pressure control system to
manage the pressure applied to both the piston placed within the liquid chamber
and to the side connection of the prototype. After analyzing different options
and taking into account the precise control of pressure needed, the use of Sen-
tronic Plus Proportional valves was considered the best choice. The operating
principle of this valve, illustrated in Figure 5.1, is summarized in three steps [131]:
• Applying pressure: The pressurization piston is operated and the flow is
released from port 1 to port 2.
• Maintaining pressure: The exhaust piston is in its central position: the flow
between port 2 and port 1 or port 3 is blocked.
• Exhausting pressure: The exhaust piston is lifted and the flow from port 3
to port 2 is released.
Figure 5.1: Operating principle. Source: Asco Numatics [131].
The nebulizer prototypes designed and manufactured in the current thesis
have two independent connections, where pressure is applied to the piston placed
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within the liquid chamber and to the side connection of the prototype, respectively.
Therefore, two proportional valves have been installed to provide an independent
pressure control in real time to each connection of the prototype.
• A proportional control valve, with an operating range of 0-500 mbar, to
control the emptying time of the liquid chamber and, therefore, the
nebulization velocity.
• A proportional control valve, with an operating range of 0-100 mbar, to con-
trol the compreesed air pressure that will produce the liquid breakup
and will generate the aerosol.
Figure 5.2: Experimental setup with the Sentronic valves.
The experimental setup developed with the pressure control system includes
the following elements: (See Figure 5.2).
1. A 24V power supply.
2. A pressure regulator to control the maximum allowable pressure admitted
by the proportional control valves (2 bar).
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3. A Sentronic Plus proportional control valve (control the compressed air
through the side connection of the prototypes).
4. A Sentronic Plus proportional control valve (control the pressure applied to
the piston placed within the liquid chamber).
5. A voltage control (0-10 V).
At the end of this thesis, the experimental setup with the pressure control
system has been prepared for the development of future experiments with the
latest prototypes manufactured. Figure 5.3 shows a prototype connected to both
proportional control valves. The control parameters can be changed with the
Data Acquisition Software (DaS) associated with the valves in order to adapt the
application of pressure through the prototype in real-time.
Figure 5.3: Prototype connected with Sentronic valves.
5.2.3 Digitalization of a Real Trachea Geometry
During the course of this thesis it was considered interesting to obtain a trachea
geometry for future CFD studies and to create a 3D model with additive manu-
facturing techniques, as the work presented by Richard et al. [132]. To that end,
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the animal experimental unit of BioCruces Health Research Institute provided a
sample of a pig trachea segment. Then, the sample was digitized with the help of
the Graphic Design and Engineering Projects deparment of the University of the
Basque Country UPV/EHU [133].
Initially, the trachea segment was split in order to be able to scan the internal
geometry. However, an incision would deform its inner shape due to the soft
organic tissue composition of the trachea. To minimize this situation, the external
part was previously scanned and two rigid plastic shells with the external trachea
shape were created with additive manufacturing techniques, as shown in Figure
5.4a. Then, the inner surface of the trachea segment was scanned by means of
structured blue light to filter out interfering ambient light. This task was carried
out by the ATOS Compact Scan M5 hardware, from GOM Gmbh manufacturer,
and by the Geomagic Design X software, from 3D Systems Corporation.
The post-process of the 3D scan data consists of several steps: the point clouds
were treated and optimized, the interior surfaces were extracted, the two halves
were joined together using rhe initial scan and shells as reference and finally it
was exported to a CAD format, that will be compatible for the CFD software in
future studies.
Figure 5.4: (a) Trachea digitalization.
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Appendices

APPENDIX A
Nebulizer Prototypes
Designs
This Appendix includes the drawings with all the geometrical details of the proto-
types designed and manufactured by means of additive manufacturing techniques
by the company OPTIMUS 3D.
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APPENDIX B
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